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Abstract
Molecular design and modeling can provide stringent assessment of our understanding of the structure
and function of proteins. Due to the subtleness of the interactions that largely stabilize proteins,
computational methods have been particularly valuable in establishing practical, formal and physically
grounded protocols to study the structure and function of these biomolecules. Especifically,
computational protein design seeks to identify sequences that fold into a desired structure and have
specific structural and functional properties using computational methodologies. Among current
techniques, an entropy-based formalism that efficiently determines the number and composition of
sequences satisfying a predefined set of constraints seems particularly promising and powerful.
Complementary to this methodology are the well-established molecular dynamics simulation techniques
that have been extensively used to study structure, function and dynamics of biologically relevant
systems. Herein different studies of systems using computational techniques to address particular
molecular problems are described. Efforts to redesign membrane proteins to generate water-soluble
variants were applied to a widely studied pentameric ligand-gated ion channel, the nicotinic acetylchoilne
receptor (nAChR). NMR structures and binding studies demostrated the robustness and applicability of
the computational design approach. Toward the creation of water-soluble variants of a G protein–coupled
receptor (GPCR), comparative modeling and docking calculations were used to investigate the structure
of the human μ opioid receptor and presented in light of previous mutagenesis studies of structure and
agonist-induced activation. Candidate peptides for possible therapeutic agents were computationally
analyzed. Peptide design, loop modeling and MD simulations were applied to investigate the stromal cellderived factor-1&a; (SDF-1&a;). SDF-1&a; displays promising therapeutic benefits to treat blood-supply
related heart disease and elicit growth of microvasculature. Simplified analogs of SDF-1&a; exhibit
enhanced therapeutic properties in cell-based assays. MD simulations provide insights about the
molecular features of this enhancement. One simplified peptide offers a potentially clinically translatable
neovasculogenic therapy. Lastly, MD simulations were utilized to analyze a molecule with hindered
internal rotors, a tribenzylamine hemicryptophane. The molecule was characterized by different
experimental and computational techniques. The structural and dynamic features of the
hemicryptophane molecule make it an attractive starting point for controlling internal rotation of aromatic
rings within molecular systems.
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ABSTRACT

COMPUTATIONAL PROTEIN DESIGN AND MOLECULAR DYNAMICS SIMULATIONS: A
STUDY OF MEMBRANE PROTEINS, SMALL PEPTIDES AND MOLECULAR SYSTEMS

José Manuel Pérez Aguilar

Jeffery G. Saven

Molecular design and modeling can provide stringent assessment of our understanding of the
structure and function of proteins. Due to the subtleness of the interactions that largely
stabilize proteins, computational methods have been particularly valuable in establishing
practical, formal and physically grounded protocols to study the structure and function of these
biomolecules. Especifically, computational protein design seeks to identify sequences that fold
into a desired structure and have specific structural and functional properties using
computational methodologies. Among current techniques, an entropy-based formalism that
efficiently determines the number and composition of sequences satisfying a predefined set of
constraints seems particularly promising and powerful. Complementary to this methodology
are the well-established molecular dynamics simulation techniques that have been extensively
used to study structure, function and dynamics of biologically relevant systems. Herein
different studies of systems using computational techniques to address particular molecular
problems are described. Efforts to redesign membrane proteins to generate water-soluble
variants were applied to a widely studied pentameric ligand-gated ion channel, the nicotinic
acetylchoilne receptor (nAChR). NMR structures and binding studies demostrated the
robustness and applicability of the computational design approach. Toward the creation of
water-soluble variants of a G protein coupled receptor (GPCR), comparative modeling and
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docking calculations were used to investigate the structure of the human

opioid receptor and

presented in light of previous mutagenesis studies of structure and agonist-induced activation.
Candidate peptides for possible therapeutic agents were computationally analyzed. Peptide
design, loop modeling and MD simulations were applied to investigate the stromal cell–derived
factor–1

(SDF–1 ). SDF–1

displays promising therapeutic benefits to treat blood-supply

related heart disease and elicit growth of microvasculature. Simplified analogs of SDF–1
exhibit enhanced therapeutic properties in cell-based assays. MD simulations provide insights
about the molecular features of this enhancement. One simplified peptide offers a potentially
clinically translatable neovasculogenic therapy. Lastly, MD simulations were utilized to analyze
a molecule with hindered internal rotors, a tribenzylamine hemicryptophane. The molecule
was characterized by different experimental and computational techniques. The structural and
dynamic features of the hemicryptophane molecule make it an attractive starting point for
controlling internal rotation of aromatic rings within molecular systems.
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Introduction

Proteins play crucial roles in the cellular physiology of a living organism with a wide
diversity of biological functions, including storage and transport of different particles, catalysis
(enzymes), transmission of information (hormones), control of flux of molecules across the
membrane, immune responses, control of gene expression, and structural support [1].
To have biological activity, proteins must adopt specific folded three-dimensional
conformations, also denominated native conformations. The three-dimensional structure is
determined by the linear sequence of amino acids in the protein backbone [2]. The description
of the spontaneous formation of a unique highly ordered three-dimensional structure from the
complete unfolded polypeptide chain comformations has been denominated the protein folding
problem [3].
Complementary to the protein folding problem is the approach of finding an
“appropriate” set of amino acid sequences that fold into a desired target structure in a similar
way as a native conformation with the lowest accessible free energy. Furthermore, such
“appropriate” sequences will not simultaneously fold to alternative competing conformations of
similar free energy [4,5]. In other words, instead of starting with a specific amino acid
sequence and then predict the folded structure of the native conformations, the protein design
paradigm starts with a conformation of the backbone and then selects amino acid sequences
that stabilize the native three-dimensional conformation. This inverse approach, sometimes
denominated inverse protein folding problem [4,5], is the purpose of the current efforts of the
protein design field [6-9].
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1.1 Computational Protein Design
Early protein design efforts involved the design of small proteins using empirical
knowledge obtained from structural databases and/or biochemical experiments. Often a
hierarchical approach was utilized, where sequences with likelihood to form particular regular
local substructures were assembled with an eye toward a specific tertiary structure [7,8]. The
results yielded impressive findings, but very often, protein-like systems with structural and
themodynamic properties less well defined than those of natural proteins, were obtained.
The interactions within a structured protein can have many levels of complexity
making protein design approaches difficult or impractical, particularly given the large numbers
of possible sequences. Proteins contain tens to thousands of amino acid residues, and even
for a single sequence, many conformations of the backbone are plausible. Furthermore, just
for a single backbone structure, an exponentially large numbers of side chain conformations
are possible. In addition, the native conformations of proteins are largely stabilized by
noncovalent forces: van der Waals, hydrophobic, electrostatic, and hydrogen bond
interactions. Given the subtlety of these interactions, reliable assessments of stability with
respect to unfolded states can be difficult to estimate. Finally, the large numbers of potential
protein sequences can lead to combinatorial complexity in protein design, e.g., using the 20
naturally occurring amino acids, a 100-residue protein has more than 10
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possible

sequences.
To address and overcome many of these difficulties, computational methods have
been developed for the design of proteins. Most methods use as input a target structure,
which can be a naturally ocurring one or one created de novo via computational modeling. To
quantify interations within a given conformation and assess the compatibility between potential
sequences and a selected structure, energy-based objective functions are used. The methods
can then identify individual sequences or properties of sequences from a large ensemble likely
to possess desirable structural and functional properties. Optimization-based methods for
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identifying such low-energy sequences utilize Monte Carlo simulated annealing, dead-end
elimination, and genetic algorithms [9-12]. Alternatively, probabilistic methods characterize an
ensemble of sequences and use ideas derived from statistical thermodynamics to estimate the
site-specific probabilities of the amino acids at variable sites within the protein [12-14].
In this regard a statistical entropy-based formalism has been developed to estimate a
set of amino acid probabilities for a specific backbone structure. This theory uses concepts
from statistical thermodynamics to calculate the site-specific probability profiles compatibles
with the given backbone structure. An effective entropy function quantifies the sequence
variability consistent with the target structure. The most probable set of site-specific
probabilities is determined by maximazing this effective entropy subject to centain constraints
[15-17].

1.2 Molecular Dynamics Simulations, Comparative Modeling and Docking Calculations
Molecular dynamics (MD) simulations have been extensively used to estimate
equilibrium and dynamic properties of proteins [18-21]. MD simulation is the computational
approach to statistical mechanics and the methodology utilized is simple in principle [22]. This
approach simulates motions of the system in consideration under the influence of a specific
force field. Configurations in time are generated by integration of classical equations of motion
[22]. By following the dynamics of a molecular system in space and in time, estimations of
equilibrium and dynamic properties of the system can be obtained. Such information
concerning structural and dynamic properties includes molecular geometries and energies,
atomic fluctuations, rates of configurational changes, free energies, and concerted global
motions [18-21,23].
In the case of proteins, all-atom MD simulations have been used to provide highresolution information of the motions of these important biological macromolecules. These
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atomistic models are used to calculate statistical properties of the system that can be tested
experimentally. Recent advances in computer software and hardware have increased the
structural complexity and time scale simulations of the studied systems [24-28].
Many other computational tools for exploring atomic and molecular properties can
complement the MD simulations approach. Some include Monte Carlo simulations, PoissonBoltzmann anaysis, energy minimization, docking calculations, and molecular modeling.
Comparative (homology) modeling provides information of the three-dimensional
protein structure, particularly for proteins that are difficult to obtain by experimental procedures
such as X-ray crystallography and protein NMR structural studies. Using the comparative
modeling approach, a three-dimensional model of a protein where the structure is unknown,
can be created using one or more related proteins of known structure as templates. The main
condition for obtaining a useful model is that the similarity between the target sequence and
the template(s) sequence is detectable somehow (e.g., sequence similarity). Additionally, a
correct alignment between the sequences is also essential. The comparative modeling
approach is based on the notion that a small change in the protein sequence usually results in
a small change in its tertiary structure [29]. In recent years template based protein modeling
techniques have produced encouraging results [30-32]. Particularly relevant is the state of the
art of comparative modeling for G protein-coupled receptors (GPCR), which has taken
advantage of the currently increasing structural information from this membrane protein family
[30,31].
The molecular docking method is extensively applied in protein systems with special
relevance in rational drug design [33]. The methodology attempts to predict preferred poses or
orientations of one structure (e.g., a drug-like molecule) forming an intermolecular complex
with a second structure (e.g., protein receptor). Information about the preferred orientations of
the structure in an intermolecular complex may be used to estimate the strength of association
or binding affinity of the structures. Most docking algorithms can generate a large number of
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possible associated structures, thus the technique requires a way to discriminate
intermolecular structures in order to identifiy those of most interest. In a nutshell, we can state
that the docking problem is related with the generation and assessment of reasonable
structures of intermolecular complexes [34-36]. Successful studies relevant to the work in this
thesis include GPCRs, potassium channels, protein kinases, protein tyrosine phosphatase,
integrin

V 3,

and G proteins [37].

1.3 Thesis Overview
Although the entropy-based formalism for computational protein design was the main
technique used during most of the studies described herein, it was complemented by other
computational techniques including comparative modeling, docking calculations, and specially
all-atom MD simulations.
First in chapter 2, a detailed description of the entropy-based formalism used for
computationally design of proteins is described. A description of the determination of the sitespecific amino acid probabilities and the different constraints that modulate the sequence
design are provided.
In chapter 3, the entropy-based protein design method was applied to redesign the
transmembrane domain of the

subunit of the nicotinic acetylcholine receptor (nAChR). The

hydrophobic protein exterior was redesigned so as to have exterior residues that are
consistent with each other and with those expected on the surface of a water-soluble protein.
The NMR structure of the computationally designed water-soluble structure (WSA) was solved
and findings regarding the structure are discussed. Interactions with anesthetics and lipids are
also analyzed. Preservation of binding sites for anesthetics and lipids in the water-soluble
variant are discussed with regard to experimental findings in membrane-soluble proteins.
The structure of the human

opioid receptor (a G protein-coupled receptor, GPCR)

was built by comparative modeling techniques using recent structural information (Chapter 4).

5

Previous mutagenesis findings are discussed in the context of the structure. Assessment of
the benefits of using different number of templates in the construction of the models is
provided. Docking calculations of a typical antagonist (naloxone) and agonist (morphine) are
described. Lastly, predictions of the agonist-induced activation are suggested.
Chapter 5 describes the design, experimental evaluation and MD simulations of
stromal cell–derived factor–1

(SDF–1 ) and simplified analogs toward the generation of

effective therapeutic agents to treat inadequate blood-supply (ischemia) related heart disease.
Analogs of SDF–1

were computationally modeled to simplify the protein structure. The

simplified analogs were experimentally characterized in cell-based assays. A simplified analog
where the central region was replaced by a two-proline linker was further characterized in a
murine model of ischemic heart failure. All-atom MD simulations were carried out in SDF–1
and the simplified analogs at physiological conditions of temperature and pressure. For the
simplified analogs, structural insights related with the different “success” in mimicking the
beneficial therapeutic properties of SDF–1 are discussed.
Lastly, MD simulations were carried out to analyze the properties of a gyroscopeinspired molecule (Chapter 6). From NMR experiments, the structural dynamics of the novel
gyroscope-inspired tribenzylamine hemicryptophane molecule indicated rigidity in one of the
components (CTV stator). Also, a hindered motion of the three rotators was observed at room
temperature. MD simulations showed close agreement with these experimental findings.
Comparison with experimental results corroborates the utility of MD simulations in providing
atomic details of molecular phenomena. Details about the rotation energy barrier and the
correlation of the three rotators are discussed.
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2

Probabilistic Theory of Computational Protein Design

2.1 Statistical Theory of Sequence Ensembles
Identifying the properties of sequences compatible with a predetermined backbone
structure would provide ways to probe the determinants of protein folding and identify folding
amino acids sequences [1,2]. A probabilistic theory has been previously introduced to explore
and characterize sequence space for a target structure without explicitly tabulating all
sequences [3,4]. The statistical entropy-based formalism has been developed to determine a
set of amino acid probabilities for a chosen backbone structure. This approach laverages
concepts from statistical thermodynamics to estimate site-specific probability profiles
compatible with the given backbone structure [1].
To adress the energetic sequence compatibility with regard to the backbone structure,
the methodology includes several scoring functions. In addition to an atom based potential
(physically derived), knowledge based potentials can be included to modulate centain
properties of the system such as secondary structure preference and hydrophobicity. The
sequence conformational space can be readily explored by the method and as a
100

consequence, large systems (> 100 residues; for 100-residue protein, 20

10

130

possible

sequences) can be considered in the protein design calculations. The method yields the
probabilities of each amino acid at each of the positions of interest in a given protein structure
and not only a specific sequence (oftentimes, the minimum energy solution) [5]. The generality
of the method allows different prerequisites for foldable sequences or arbitrary constraints
such as patterning of hydrophobic residues to be included.
In specifying the sequence identity and energetic conformations subject to certain
constraints for a specific folded state, the probability of amino acid

at position i and with a

side chain in a conformation state defined by r( ), is denoted by wi( ,r( )). The total
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sequence-conformational entropy function S that quantifies the variability of sequences
consistent with a particular target structure is defined by equation 2-1.

w i ( ,r( )) ln w i ( ,r( ))

S=
i

(2-1)

,r( )

The expression considers each of the sequence position i and all available amino acid
identities

. For each amino acid identity

, the expression also considers all the possible

rotamer states r( ) [6]. The residues state probabilities are obtained by maximizing this
effective entropy function subject to different constraints. The maximization is done using the
Lagrange multipliers method [7]. The variational functional of the set of probabilities wi( ,r( ))
is defined by equation 2-2.

V =S

f

1 1

f

(2-2)

f

2 2

3 3

The constraint functions fk specify global and local features of the sequence-structure space
and are in general, function of the probabilities wi( ,r( )) .

k

are the respective Lagrange

multipliers. To identify the probabilities consistent with particular value(s) of the constraint(s) fk,
0

the constraint function is restrained to have a particular value fk .

f k0 = f k ({w i ( ,r( ))})

(2-3)

The large set of coupled nonlinear equations that determine the set of state probabilities

{wi( ,r( ))} and the Lagrange multiplier

k

associated with the contraints are defined by

equations 2-4 and 2-5.
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0=

0=

wi (

V
,r( ))

(2-4)

V

(2-5)

k

2.2 Constraints
2.2.1 Energy Functions
Conformational energy function E that quantifies sequence-structure compatibility is
determined using a molecular mechanics force field [8]. This conformational energy is
composed of non-bonding interactions including van der Waals (using a Lennard-Jones 12-6
potential), electrostatics with a distance dependent dielectric constant ( = 4 0rij where rij is the
interatomic distance), and a modified angular-dependent hydrogen bond term [9] (additionally,
a torsional energy term for the side chains is sometimes included as one body term, see
equation 2-6). For a particular sequence of N sites (
conformational states of the each amino acid are (r(

1),…,

1,…, N)

r(

N)),

where the side chain

the conformational energy

E can be expressed as a one-body and a pairwise two-body terms, equation 2-6.

(1)
i

E=

(

(2)
ij

,r( )) +

(

,r( ); ',r( '))

(2-6)

i< j

i

The first term contains the one-body contribution

(1)
i (

,r( )) and includes the interaction

between backbone and amino acid side chains. Additionally, it contains the reference energy
that accounts for the unfolded state contribution, see section 2.2.2. The second term contains
the two-body contribution

(1)
ij

( ,r( ); ’,r( ’)) and includes all the interaction energies
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between amino acid side chains r( ) and r( ’) at site i and j, that is two different rotamer
states at two different sites in the structure.
Within the context of the statistical theory, for a given set of sequences, the
assumption that the fluctuations in the conformational energy around the main value (due to
variability of sequence) are small is reasonable. The conformational energy can be writen as
equation 2-7.

(1)
i

E
i

(

,r( )) w i ( ,r( )) +

,r( )
(2)
ij

i< j

(

(2-7)

,r( ); ',r( ')) w i ( ,r( )) w j ( ',r( '))

,r( ) ',r( ' )

2.2.2 Reference Energy
The paradigm in protein design is to optimize the energy of a particular sequence in
the folded structure. In order to discriminate among a large number of possibilities, information
about the energetics of the folded and unfolded states must be considered [2]. The
discrimination of different sequences is carried out relative to the energy of the ensemble of
unfolded states [2,10]. The calculation of the energy of the ensemble states is very complex
even for small systems. To address this difficulty, a reference energy

ref

is introduced to

account for the energetics of the unfolded states, equation 2-8. Using the structure:
N acetyl ( ) N’ methylamide, the Helmholtz free energy is calculated for each amino acid
( ) over different possible rotamer states r( ) and backbone degrees of freedom ( ,

). In

particular, the calculation of the partition function zref at a given temperature T for each of the
amino acids involves the sum of the conformational energy over different rotamers states and
variations of the backbone degrees of freedom ( ,

). The different rotamer states are those

from a backbone dependent rotamer library [11]. The variations of the
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and

angles involved

increments in 10° from 0 to 2 , equation 2-9. The results for the reference energy

ref

for the

different amino acid residues are expressed with respect to the value for glycine.

ref

( ,T) = kB T ln

zref ( ,T) =

zref ( ,T)
zref (Gly,T)

exp
,

r( )

ref

(

, ,r( ))
kB T

(2-8)

(2-9)

Since the reference energy is just a function of the amino acid type at each site, this
term that accounts for the contributions of the unfolded states is introduced directly in the
effective one-body term in equation 2-7. Consequently, the energy contraint that involves
interatomic interaction can be rewritten as equation 2-10.

( (
(1)
i

E
i

,r( ))

,r( )

(2)
ij

+
i< j

(

ref

( ,T)) w i ( ,r( ))

,r( ); ',r( ')) w i ( ,r( )) w j ( ',r( '))

(2-10)

,r( ) ',r( ' )

2.2.3 Environmental Energy
To account for solvation effects and for the tendency of different amino acids to be
exposed to or sequestered from water (hydrophobicity), an additional contraint was
introduced, herein environmental energy ( Eenv) [4]. This energy term is based on the local
density of C atoms of each residue in the fixed protein scaffold. Generally in a folded
structure, hydrophobic residues tend to be sequestered from the solvent and as a
consequence, surrounded by a large number of neighbors. The number of C atoms in the
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vicinity of these buried residues is relatively large. On the other hand, hydrophilic residues are
prone to be located at the surface positions where they are highly exposed to water
molecules. In this case, the amount of neighbors and thus, the number of C atoms in their
vicinity, is relatively low. The choice of C density is convenient not only because this quantity
is invariant for a specific fixed backbone structure but also because the implementation is
complatible and consistent with the statistical implementation described in section 2.1 [4]. The
effective local environmental energy is defined by equation 2-11.

env

Where
type

env

( ,r( ); ) = k B T ln

f( , )
f( )f( )

(2-11)

is the effective local environmental energy that depends on the amino acid

with particular rotamer state r( ) and the specific C density environment . f( , ) is

the fraction of times a local C density

, is observed for the amino acid type

. f( ) is the

is observed in the globular protein training set used for the

fraction of times a local density

parametrization. f( ) is the fraction of times a local density

is observed irrespective of the

amino acids type. The protein-training database was composed of 500 representative globular
protein structures (http://www.cbrc.jp/pdbreprdb-cgi/reprdb_query.pl), see details in reference
[4]. The local C density

(equation 2-12) is defined as the density of C atoms within the free

volume of a sphere of radius Rc centered at the center of mass of each side chain. The free
volume is referred as the volume not excluded by the side chain and its respective peptide
main chain.

( )=

n (C ,R)
4
3

Rc3

Vaccess ( )
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(2-12)

Here n is the number of C atoms within a specified volume of radius R and Vaccess( ) is the
average volume not excluded by the side chain of

, where the average is taken over all

possible rotamer states r( ). The average value of the C density

( ) for each amino acid

was found to correlate well other scales of hydrophobicity [4,12].
Within the context of the statistical theory, the environmental energy is defined by
equation 2-13. Noteworthy, for a fixed backbone, Eenv( ,r( )), which depends on both the
amino acid type and the rotamer state, is expressed as one-body term. The calculation of the
environmental energy in the globular protein-training set correlated well with the length of the
0

protein (number of residues). During the sequence probability calculation, the target E

env

is

constrained to a value in concordance with the linear relationship found in the globular protein
set between the value of the environmental energy and the number of residues of the system.
The ensemble environmental energy Eenv is optimized so as to satisfy the target value of the
0

environmental constraint E

env.

0
E env
= E env =

env
i

(

,r( )) w ( ,r( ))

(2-13)

,r( )

2.2.4 Diversity Entropy Potential
During the framework of the statistical method in protein design, the selection of a
final sequence is usually carried out by using the most probable amino acids at each of the
target positions. Sometimes, different criteria are used to obtain the final consensus
sequence. In the case of buried positions, the environment exerts restraints that tend to bias
the preference for some amino acids. In these positions, a distinctive and easy to interpret
probability distribution is frequently observed. On the contrary, in the case of highly exposed
positions, the solutions obtained in the statistical calculations frequently display unbiased
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distributions for the amino acid probabilities. Polar or charged amino acids exhibit very similar
probabilities and are slightly preferred than non-polar amino acids. Depending upon the
purpose of the design, sometimes a more diverse sequence is desired as in the case of NMR
experiments where such diversity should yield dispersion in the NMR spectrum and facilitate
structure determination. To increase the amino acid diversity, an additional constraint
consistent with the statistical methodology was introduced. This constraint, denominated
diversity entropy potential SI, was implemented as an inverse participation ratio.

SI =

1
=
meff

f 2( )

(2-14)

n

w i ( ,r( ))
f( )=

i=1

(2-15)

n

Here, f( ) is the frequency with which amino acid
defined as the probability of amino acid

appears among the sequences and is

summed over the n targeted positions (targeted

positions are usually all the positions selected to be mutated during the design). The number
of possible amino acids, m, is m = 20 if all the naturally occurring amino acids are permitted.
The effective number of amino acids that appear at the targeted sites, meff, can be defined
using the calculated amino acid probabilities; meff is bounded 1

meff

m and it represents an

average over the ensemble of sequences. For a homopolymer where only one amino acid is
used to construct the sequence, meff = 1; if all 20 amino acids appear with equally frequency,

meff = 20. Thus meff may be viewed as the effective number of amino acids used to construct
the sequences.
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2.3 Site-Specific Amino Acid Probabilities
In solving the coupled nonlinear equations that maximize the conformational entropy
function subject to certain constraints, the site-specific probabilities and the associated
Langrange multipliers to those constraints are determined.

w i ( ,r( ))

wi ( ) =

(2-16)

r( )

The set of probabilities are obtained at different effective temperatures

-1

, where

Lagrange multiplier associated with the conformational energy constraint. At

is the

equal to 0.5

mol/kcal the sequence properties are found to be robust with respect to slight changes in the
backbone structure [4].
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3

NMR Structure and Dynamics of a Computationally Designed

Water-Solubilized

Transmembrane

Domain

of

the

Nicotinic

Acethylcholine Receptor (nAChR) 1, 2

3.1 Introduction
Nicotinic acetylcholine receptors (AChRs) belong to a superfamily of neurotransmittergated ion channels, which also include glycine (Gly), -amino-butyric acid type A (GABAA),
and serotonin (5-HT3) receptors. These receptors, composed of five homologous subunits in a
pentameric assembly, mediate fast synaptic transmissions. All subunits comprise of a large
extracellular domain, four transmembrane (TM) domains, and a long intracellular loop linking
the third and fourth TM domains [1,2]. Mutagenesis and functional investigations have showed
that binding of at least two agonists at the interfaces of the extracellular domains triggers the
channel opening, allowing ions to pass through a TM pore surrounded by the TM2 helices
from the five subunits.

1

This project was a collaboration with the group of Professor Roderick G. Eckenhoff at the
Department of Anesthesiology and Critical Care Medicine, University of Pennsylvania
Perelman School of Medicine, Philadelphia, PA 19104 and the group of Professor Yan Xu at
the Department of Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, PA
15260.
2
Adapted from Tanxing Cui, David Mowrey, Vasyl Bondarenko, Tommy Tillman, Dejian Ma,
Elizabeth Landrum, Jose Manuel Perez-Aguilar, Jing He, Wei Wang, Jeffery G. Saven,
Roderic G. Eckenhoff, Pei Tang, Yan Xu. Biochimica et Biophysica Acta – Biomembranes
2012, 1818, 617-626.
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The most studied member of this receptor superfamily is the highly abundant nAChR
found in the Torpedo electric organs. The Torpedo nAChR, consisting of two 1 subunits and
one each of

1, , and

subunits, is homologous to the mammalian muscle-type nAChR

responsible for the rapid signaling at the neuromuscular junction. Although no atomic
resolution structure is yet available for nAChRs, a 4-Å-resolution structure model has been
determined by the pioneering cryo-electron microscopy (cryo-EM) work on the Torpedo
nAChR [3,4].
More recently, high-resolution structural insights are gained from several crystal or NMR
structures of related proteins, including an isolated extracellular domain of the nAChR
subunit bound to

1

-bungarotoxin [5], isolated four TM domains of the nAChR 2 subunit [6],

the snail acetylcholine binding protein [7] which resembles the extracellular domain of the
nAChR, and two prokaryotic pentameric ligand-gated ion channels from the bacterium Erwinia
chrysanthemi (ELIC) [8] and the cyanobacterium Gloebacter violaceus (GLIC) [9,10]. The
overall architecture of the extracellular domains is similar among the currently available
structures. The TM domains, however, exhibit significant variation in high-resolution details.
The discrepancy among the TM domain structures may result from the difference in the
membrane mimetic environments used for the structure determination, or from the difference
in the ion-conducting states of the TM segments. It is worth noting that the 4-Å-resolution cryoEM structure of the muscle-type nAChR shows four straight long helices in the TM domains. In
contrast, the GLIC and ELIC crystal structures and the nAChR 2 NMR structure all exhibit
relatively short and curved helical structures. The cryo-EM nAChR structure is presumably in
the closed-channel state, whereas GLIC is either in a desensitized state or in a nonphysiological artificial state due to the unexpected presence of detergent molecules within the
aqueous pore. The ELIC crystal structure is thought to be in a collapsed state. Potential
interactions with cholesterols, which are present in eukaryotic membrane but absent in
prokaryotic membrane, can add another layer of complexity in TM domain structure
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determination.
The uncertainty in the TM domain structures reflects the technical difficulties associated
with the structure determination of TM channel proteins. Crystallization trials involve the use of
nonnative detergents that may or may not support the functional fold of the TM domains. The
success in the expression, purification, and crystallization of prokaryotic channels such as
ELIC and GLIC does not readily translate into practice for mammalian channels, which are
difficult to overexpress in suitable quantities for structural studies. Because of their large
hydrophobic surface in the TM segments and the need for posttranslational modifications,
mammalian channel proteins are also prone to aggregation, rendering the standard solutionphase purification methods ineffective. Most biophysical studies involve dispersing membrane
proteins in aqueous media, usually using detergents, lipids, auxiliary proteins, and other
membrane-mimetic mixtures. Obtaining conditions to achieve monodispersity for X-ray
crystallography or NMR studies remains a touchy and exceedingly time consuming process.
An alternate, systematic approach is to redesign membrane proteins to remove the
exposed hydrophobic exterior. In essence, TM proteins are transformed into soluble ones
while retaining important structural and functional features. Using computational approaches,
water-soluble variants of integral membrane proteins have been designed to facilitate
structural studies. Recently, a computationally designed water-soluble variant of the bacterial
potassium ion channel KcsA has been accomplished [11,12] and its high-resolution structure
has been elucidated by NMR [13]. The NMR structure of one of the three designed sequences
of water-solubilized KcsA (WSK3) is in striking agreement with the crystal structure of the wildtype protein [13,14]. These findings emphasize the promise of developing water-soluble
variants of membrane proteins suitable for biophysical studies and potentially for structurebased drug discovery.
In this study, we present a similar approach for the TM domains of nAChR 1 subunit.
A water-soluble variant of the TM domains was computationally designed, resulting in the
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replacement of 23 hydrophobic residues with hydrophilic ones at the lipid-exposed surface.
The resulting protein, called water-soluble acetylcholine receptor channel (WSA), was
experimentally expressed and purified, and its structures determined using high-resolution
NMR. Because the nAChRs are potential molecular targets for general anesthetics [15-19], we
also determined the binding of two representative anesthetics, azi-isoflurane and azi-propofol,
to the designed protein using photoaffinity labeling. We found that the designed protein
retained an overall four-helix bundle topology and overlapped remarkably well with the crystal
structure of the GLIC TM domains. A common binding site was identified for azi-isoflurane and
azi-propofol in the general vicinity of a propofol binding site found in the crystal structure of
anesthetic-bound GLIC. These results provide additional experimental evidence for the
general applicability of the water solubilization approach to high-resolution structural
investigation of membrane proteins.

3.2 Methods
3.2.1 Computational Sequence Design for Water Solubilization
The design principle involves the identification and redesign of exposed hydrophobic
residues in the TM domains in order to transform a membrane protein into a completely or
partially soluble protein while maintaining the structure- and function-related properties. The
redesign of the nAChR

1 subunit was based on the 4-Å-resolution cryo-EM structure model

as a template (PDB accession code: 1OED; Figure 3.1a) [3,4]. The exposed residues were
selected as those with more than 40% solvent exposure (Figure 3.1b) according to
GETAREA1.1 [20]. Residues targeted for mutation were both hydrophobic (AFILMVW) and
expected to reside in the TM region [3]. Hydrophobic residues at the interfaces between
helices within the subunit were retained as in the wild type protein.
The site-specific probabilities of the amino acids at the potential mutation sites were
calculated as described previously [11,21-25]. For each of the sites, all 20 amino acids were
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permitted while the remaining residues were constrained as wild type. Side chain
conformations were restricted to those from a library of frequently observed conformations
(rotamer states) [26] with at most 10 rotamer states per amino acid. Two energy functions,
averaged over the sequence of the entire protein, were constrained to characterize the
ensemble of soluble variants. The first energy term accounts for the inter-atomic interactions
using a molecular mechanics force field (the AMBER force field) [27]. The second term
quantifies the hydrophobic potential (environmental or solvation energy) that was constrained
to an averaged value expected for a soluble protein having the size of the TM domains of the
nAChR 1 subunit [11].
The computation for site-specific probabilities of amino acids at each mutation position
was carried out in two stages. The first stage used the most probable amino acids at each of
the targeted positions. At the second stage, only the sites where one amino acid was highly
favored (probability of an amino acid exceeding 0.8) were constrained to that most probable
amino acid. At the rest of the positions, an additional constraint was imposed to increase the
diversity of different amino acids that appear in the final sequence. Amino acid diversity is
desirable to avoid spectral over-crowding in the NMR spectra, thereby facilitating spectral
assignment and structure determination. The sequence diversity constraint was implemented
as an inverse participation ratio:

1
=
meff

m

f 2( )

(3-1)

=1
n

wi ( )
f( )=

i=1

(3-2)

n

where m is the number of possible amino acids, e.g., m = 20 if all the naturally occurring
amino acids are permitted. The function f( ) is the frequency with which amino acid
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appears among the sequences and is defined as the probability of amino acid

summed over

the n targeted positions. The effective number of amino acids that appear at the targeted sites,

meff, can be defined using the calculated amino acid probabilities; meff is bounded 1

meff

m

and it represents an average over the ensemble of sequences. For a homopolymer where
only one amino acid is used to construct the sequence, meff = 1; if all 20 amino acids appear
with equal frequency, meff = 20. Thus meff may be viewed as the effective number of amino
acids used to construct the sequences.
The current design focused on the TM domain without the extracellular domain and the
intracellular loop. The removal of the intracellular loop separate TM4 from TM1-TM3. In order
to express the designed protein as a single chain, a polyglycine linker was designed using the
loop builder in MODELLER [28]. To minimize any structural biases and effects of an artificial
linker on TM3 and TM4 and to take advantage of the additional length from the residues in the
wild-type sequence leading to the TM1 helix and ending the TM4 helix (the C-terminus), we
placed the artificial polyglycine linker between the C-terminus of helix TM4 and the N-terminus
of helix TM1 (Figure 3.1c). This arrangement preserves the orientations of individual TM
domains without restricting the relative spatial positions of TM3 and TM4, as in the topology of
the original cryo-EM template.
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Figure 3.1. Sequence Redesign. (a) Ribbon representation of the pentameric structural template (PDB
code: 2BG9) of nicotinic acetylcholine receptor (nAChR) used for the water solubilization sequence
redesign. (b) The transmembrane domain of the 1 subunit in van der Waals representation before (left)
and after (right) the computational redesign. Residues are colored by amino acid types: Green:
hydrophilic (GNQSTY); white: hydrophobic (ACFILMPVW); blue: basic (HKR); and red: acidic (DE). (c)
Cartoon representation of helix configuration in water-solubilized acetylcholine receptor (WSA). A
polyglycine linker was added between TM1 (helical N-terminus) and TM4 (helical C-terminus) so that the
TM domains can be expressed as a single chain. (d) Sequences of the transmembrane domains of
nAChR 1 subunit, two calculated water-solubilization designs, and the bacterial pentameric ion channel
GLIC are aligned for comparison. Water-solubilization mutations are marked in red. The most probable
mutations are in italic boldface. Mutations changed by the inclusion of sequence diversity constraints are
highlighted in green. Putative pore-lining residue positions are highlighted in blue. The transmembrane
domain helices in the corresponding structures are underlined for comparison. Conformation
heterogeneity in WSA is underlined with dashed lines.

3.3 Results
3.3.1 WSA Sequence Design
Using the cryo-EM structure model of the nAChR

1 subunit [3,4] as a template and

40% solvent accessibility surface as the criterion for exposed residues, we identified 29
hydrophobic residues within the TM domains as potential redesign targets. Of these, six were
considered at the interfaces between the helices and kept unchanged: I219, M243, V261,
F414, I420 and V425. The remaining 23 positions were targeted for computational redesign.
They are I220, L223, L224, F227, L245, I247, L251, V255, F256, L258, V259, M282, I283,
I286, I290, V293, V294, L411, M415, L416, I419, V423, and F426.
At the first stage of site-specific probability computation, the most probable amino acids
at each of the 23 positions were calculated. The resulting sequence is shown in Figure 3.1d as
Cal_1. This sequence was found to be cytotoxic to E. coli, and the resulting expression yield
was low. In the second stage of redesign, only the positions with amino acid probability > 0.8
were constrained to the most probable amino acids. The following six mutations satisfied this
condition: L224K, F227E, L245E, V259K, I290K and I419K. At the remaining 17 positions,
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sequence diversity constraints were used according to Eq. (3-1) and Eq. (3-2). With 23
variable residues, the site-specific probabilities yield meff = 4.3 in the absence of any
constraints on diversity. With the mutations at the above six positions fixed, the constraint is
applied so as to achieve meff = 5.0. The most probable amino acid was selected at each of the
17 variable positions, yielding sequence Cal_2 in Figure 3.1d. This sequence has a theoretical
isoelectric point (pI) of = 6.39 [29]. Also displayed in Figure 3.1d is an aligned sequence for
the GLIC TM domains. The sequences are 83% identical between Cal_2 and the original 1
subunit of nAChR, and 11% between Cal_2 and GLIC. The residue numbering used in this
study and the corresponding sequence numbering in nAChR

1 subunit and in GLIC are

shown in Figure 3.1d.
The lengths of the polyglycine linker (4 to 8 Glys) were investigated, and 50
independent calculations for each length of loop were performed using MODELLER [28]. The
5-glycine segment had the lowest effective energy (best score in MODELLER). The quality of
the choice of loop length was also confirmed by energy minimization of the loop structures
with NAMD [30] using the CHARMM force field [31].

3.3.2 Secondary Structure of WSA by CD and NMR
Circular dichroism (CD) measurenments of the water-soluble variant in aqueous media
with 2% of lipid (1-palmitoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] (LPPG)) show
an -helical content of ~50%. Although this value is significantly lower than the helical content
of the cryo-EM template (~83-87%), it is in reasonable agreement with the estimation from
FTIR and CD measurement of the authentic full-length nAChR [32] and GlyR [33,34]. From
the NMR chemical shift index (CSI), secondary structure can be inferred. In the case of WSA,
this quantity indicates four helical segment (Figure 3.2b), with ~70% residues having a C
chemical shift consistent with an -helical secondary structure. These results are in excellent
agreement with the helical content of the transmembrane domains of GLIC. Additionally, a
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slow conformational exchange between two conformations for the segment

104

107

STSS

was

observed on the NMR timescale (Figure 3.2c).

Figure 3.2. Secondary Structure Determination. (a) Far-UV circular dichroism (CD) spectrum of WSA
in water with 2% LPPG, showing an -helical content of ~50%. (b) The NMR chemical shift index (CSI),
determined based on the backbone C

resonance frequencies relative to the random coil values, is

plotted as a function of residue numbers. Four helical domains are clearly defined. (c) Conformation
heterogeneity in the segment between TM2 and TM3 is visible in the resonance peak doubling for
residues

104

STSS

107

. SCI suggests slow exchange between helical and non-helical conformations.
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3.3.3 High-Resolution NMR Structure of WSA
The advantage of water solubilization of TM channel proteins is clearly displayed in the
NMR spectra of WSA (Figure 3.3a). Not only can WSA be expressed and purified in large
quantity for structural studies, the NMR spectra also showed that the water solubilization of
this TM protein greatly improved monodispersity of the protein sample, allowing highresolution NMR spectra to be acquired with homogenous peak intensities. Well-resolved 3D
NMR spectra permitted spectral assignment of nearly all backbone resonances and many side
chain resonances. With the exception of the segment STSS mentioned above, the majority of
residues in the WSA sequence showed one set of NMR peaks, indicating a structural
homogeneity. The structures of WSA with the STSS segment in the major and minor
conformations were determined separately using the standard solution-state NMR methods.
The 15 lowest target-function structures for each conformation are shown in Figure 3.3b
(protein data bank PDB ID code 2LKG and 2LKH for the major and minor conformations,
respectively), and the structure with minimal root-mean-square deviation (RMSD) from the rest
in the same conformation is highlighted in the ribbon representation. The overall backbone
RMSD in the four helical domains is 0.69 ± 0.13 Å and 0.93 ± 0.19 Å in the major and minor
conformations, respectively. None of the structures have a distance violation > 0.5 Å or an
angle violation > 5°, and 99.2% of the residues are in the most favored and additional allowed
regions of the Ramachandran plot and no residues are in the disallowed region. Lastly,
backbone
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N R1 and R2 relaxation parameters suggested a monomeric form of WSA.
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1

15

Figure 3.3. Structure Determination of WSA by High-resolution NMR. (a) Representative H- N
HSQC NMR spectrum of WSA acquired at 40°C on an 800-MHz spectrometer, showing well resolved
resonances of the water-solubilized membrane protein. (b) Bundles of the 15 lowest target function
structures of major (left) and minor (right) conformations. The structures with the least RMSD from the
rest of the bundle are depicted in the ribbon representation, with the TM4-TM1-TM2-TM3 domains
colored in a red-to-blue color scale. The STSS segment is highlighted in magenta, and Loop-23 in the
Cryo-EM template, which is a part of the TM3 helix in the WSA structure, is highlighted in cyan. (c)
Superposition of the WSA NMR structure (blue) onto the TM domains of the crystal structure of GLIC
(left, white) and the NMR structure of nAChR
hexafluoroisopropanol [6].
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2 subunit (right, white), which was solved in

3.3.4 Anesthetic Binding to WSA
Using photoaffinity labeling, we investigated potential anesthetic binding to WSA. Peptides
accounting for 48% of the sequence were detected for the azi-isoflurane labeled sample, and
a single adduction site was found at V-31. Similarly, peptides accounting for 67% of the WSA
sequence were detected in the aziPm labeled sample, and the same residue (V-31) was found
to be the only modified site.

3.4 Discussion
3.4.1 Structure Characteristics of WSA
We have solved the structure of a water-solubilized analogue of the TM domains of
nAChR

1 subunit using solution-state NMR spectroscopy. The protein was designed to be

monomeric in solution, permitting secondary and tertiary structures to be determined at the
atomic resolution. For clarity, we focus our discussion of the WSA structures with the STSS
segment in its major conformation. The structure shows the expected four-helix bundle fold
but with four unequal helix lengths. TM1 and TM2 are both six helix-turns long, shorter than
TM3 (9 helix turns) and TM4 (8 helix turns). In comparison, the cryo-EM structure of Torpedo
nAChR, which was used as the template in the computational sequence redesign, has four
straight helices of roughly equal lengths (8 helix turns for TM1, TM2, and TM3, and 10 helix
turns for TM4). The residues belonging to the helices as determined in the cryo-EM structure
and the WSA NMR structure, along with those in the crystal structure of GLIC, are underlined
in the sequences in Figure 3.1d for comparison. A superposition of WSA structure onto the
monomer structure of GLIC is depicted in Figure 3.3c. Although WSA has ~83% sequence
identity to the wild-type nAChR and only 11% identity to the GLIC TM domains, the highresolution NMR structure of WSA agrees more with that of GLIC than with the cryo-EM
template. This is rather unexpected. Several contributing factors can be considered. First, the
experimental conditions under which the structures were determined were very different. The
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cryo-EM structure of nAChR was determined in highly ordered tubular crystal arrays rapidly
frozen in liquid-nitrogen-cooled ethane. WSA NMR structure was determined at the room
temperature in a significantly more dynamic aqueous solution of lyso-lipids; 2% LPPG was
needed to maintain monodispersity of the NMR sample when pH was lowered to 5.8.
Similarly, GLIC was crystallized at a non-freezing temperature in ~3% n-Undecyl- -Dmaltoside detergent. Moreover, nAChR normally resides in eukaryotic membranes that
contain cholesterol, and cholesterol has been proposed to form a slowly exchangeable
structural component of this family of ligand-gated ion channels [35].

The absence of

cholesterol in WSA may therefore make it more resemblant to the GLIC structure. Hence, the
environment might play a more critical role than the amino acid sequences in affecting the
high-resolution details of the structures. The debatable question remains as to which
biophysical conditions are more relevant for membrane protein structure determination. Before
high-resolution structures can be determined under physiologically relevant conditions, all
currently available methods, including crystallography, can conceivably introduce some
degree of artifact. Second, the high-resolution difference between WSA and cryo-EM nAChR
structures may result from different equilibriums of conformational states. The cryo-EM
structure is believed to mainly capture the closed state of the channel [3], whereas GLIC
crystal is thought to be in either an open or desensitized state [9,10]. Because WSA structure
was determined as a monomer, its conformational state can only be inferred. The fact that
WSA structure agrees so well with the GLIC structure suggests that WSA monomer may
reflect the conformation of the open or desensitized state of nAChR TM domains. Third, there
is also a possibility that WSA structure is distorted due to the truncation of extracellular and
intracellular domains or due to water solubilization itself. This scenario is very unlikely,
however, given the agreement between WSA and GLIC structures. GLIC was determined as
an intact channel protein. Taken together, our results suggest that water-solubilization of
membrane proteins is not less relevant for structure determination than other more

34

conventional lipid or detergent solubilization approaches. The ease in protein expression and
purification and, more importantly, the greatly improved spectral quality of the resulting
proteins after water solubilization, make water solubilization an attractive alternative. We
believe that the NMR structures of water-solubilized proteins, including WSK3 published
previously [13] and WSA determined in this study, represent the first approximation of the
native structures. These structures provide the high-resolution templates for further refinement
by other biophysical means.

3.4.2 Dynamic Characteristics of WSA
It is conceivable that water solubilization of membrane proteins can change the
motional characteristics of these proteins. For WSA, several residues in the TM2 domain were
mutated from hydrophobic to charged amino acids for the purpose of promoting monomeric
form in order to increase NMR spectral resolution. There are seven mutations in the TM2
helix, four of which, L89K (L9’K), V93E (V13’E), L96K (L16’K), and V97K (V17’K) (see Figure
3.1d for relative numbering of TM2), are located at the putative pore-lining sites of the nAChR
channel. The charged residues likely prevent the formation of oligomerization by TM2. Without
association with other TM2 helices, TM2 domain becomes particularly dynamic in WSA.
Although the increase in dynamics of TM2 in WSA is undoubtedly the result of water
solubilization, the fact that other TM domains do not experience the same degree of increase
suggests that the motional characteristics of TM2, controlled by Loop-12 and Loop-23, might
be intrinsically different from the rest of the protein. Indeed, it has been suggested that nAChR
TM domains can be separated into inner helices, comprised of TM2 domains, and outer
helices, comprised of TM1, TM3, and TM4 helices [3]. Channel gating is thought to involve the
movement of the inner helices relative to the outer helices.
The dynamics of the two loops, Loop-12 and Loop-23, deserves further examination. As
shown in Figure 3.1d, the WSA loop regions coincide more with those in GLIC structure than
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in nAChR cryo-EM structure. Loop-12 consists of five residues L73-S77 (LPTDS) in WSA,
different from the very tight, three-residue turn (SGE) in the cryo-EM structure. The loop
residues are also shifted. Loop-12 in WSA is a part of the TM1 helix in nAChR cryo-EM
structure, whereas Loop-12 in the cryo-EM structure forms the beginning of the TM2 helix in
WSA. The NMR dynamics measurements show that the segment from Y72 to K80,
encompassing Loop-12 in both the WSA (LPTDS) and cryo-EM (SGE) structures, is highly
flexible. Although the Loop-12 conformation as shown in the NMR structures is the preferred
conformation based on the NMR data, the shifted Loop-12 conformation as displayed in the
Cryo-EM structure is also possible. Nevertheless, we believe that the Loop-12 conformation
as shown in the NMR structures, with P74 in the loop instead of in the TM1 helix, is the
dominant loop population in the conformational equilibrium.
Similarly, Loop-23 between TM2 and TM3 domain is also highly dynamic. In the intact
receptor, this loop is believed to interact with the Cys-loop and 12 loop in the extracellular
domain to mediate ligand binding to channel gating [17,18,36,37]. In WSA structure, TM2 helix
ends at E20’, whereas in Cryo-EM structure the TM2 helix extends to the extracellular space
and ends at S27’ or A28’. None of the high-resolution structures solved so far for Cys-loop
receptors, including the WSA structure solved in this study, the NMR structure of the nAChR
2 subunit TM domains [6], the high resolution NMR structures of glycine receptor TM2-TM3
domains solved in DMPC/DHPC bicelles [38], the crystal structure of GLIC [10], and the
crystal structure ELIC [8], agree with the cryo-EM structure in this region. Our dynamics data
suggest that several conformations can co-exist in Loop-23. Even with water solubilization, the
dynamic characteristics seem to have been preserved. High-resolution NMR spectra of
pentameric glycine receptor TM domains in lyso-lipid micelles also exhibit peak doubling in
this segment (data not shown), suggesting that slow conformational exchange is an intrinsic
dynamic feature in the region between TM2 and TM3 helices. The conformation heterogeneity
of Loop-23 may be required for the TM2 movement during channel gating.
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3.4.3 Anesthetic Binding to WSA
To further confirm similarity of WSA to GLIC, we performed binding studies. Recently,
X-ray structures of GLIC were solved with two different general anesthetics—propofol and a
haloether, desflurane—bound [39]. Like GLIC, nAChR is also sensitive to general anesthetics,
so confirmation of anesthetic binding will provide a functional measure of the fidelity of the
water solubilization paradigm. We found that both propofol and a haloether photolabels bound
to the same residue (V31) in the WSA structure (Figure 3.4). Also highlighted in this figure are
residues that border the propofol-binding site in the GLIC-anesthetic co-crystal structure. The
agreement with respect to the Z-direction along the bundle is remarkable. Although the side
chain of V31 is oriented away from the intrasubunit GLIC anesthetic site, we have prior
evidence suggesting that backbone carbonyl atoms are preferred photoadduction sites [40],
especially for residues with apolar hydrocarbon side chains. The V31 carbonyl oxygen is
oriented such that it is easily accessed from the intrasubunit cavity. Thus, it would appear that
the anesthetic site in GLIC and WSA is similarly positioned within the bundle. This result
further validate the water-solubilization approach: mutation of surface residues to improve
water solubility does not greatly alter the overall fold and internal packing of the protein,
preserving potential drug binding sites or structure-based drug screening. However, it is
important to note that neither propofol nor isoflurane binding site has been definitely located in
nAChR, thus we cannot yet conclude with confidence that the WSA site well represents that in
the native nAChR.
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Figure 3.4. Comparison of Anesthetic Binding Site in WSA and in GLIC. The WSA structure
(magenta) is fitted to the TM domain of the crystal structure of GLIC (yellow). The anesthetic binding site
in WSA was determined by photoaffinity labeling. Both Azi-isoflurane and Azi-propofol bind to residue
V31 located in TM4 (cyan). The dominant propofol binding site in GLIC crystal is highlighted in orange.
Notice that the general location of the binding sites is essentially the same, suggesting that the drugbinding site is preserved in the water-solubilized protein.

3.4.4 WSA-Detergent Interaction Site
Although WSA was soluble in water at high pH, lowering pH to pass the theoretical
isoelectric point (pI) for NMR experiments can lead to soluble aggregations. To maintain WSA
monodispersity in the NMR sample, 2% of the lyso-lipid LPPG was used. Previous
experimental and computational studies have suggested that nicotinic acetylcholine receptor
requires the proper compositions of lipids in order to function. The location of lyso-lipid
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molecules in WSA thus can provide structural information about protein-lipid interaction. We
found that several residues at the TM1 and TM4 interface have cross peaks with LPPG.
Specifically, residues 48, 50, 64, and 67 of TM1 and residues 24, 33, 34, 35, 39, 40, 41, and
43 of TM4 border an interfacial cavity that can accept a lipid molecule. The same cavity can
be found in nAChR cryo-EM structure and in ELIC and GLIC X-ray structures. As shown in
Figure 3.5, the superposition of WSA and GLIC reveals that the strong WSA-LPPG interaction
site coincides nearly perfectly with location where surface lipid molecules were found in the
GLIC crystal. This finding indicates that despite water solubilization, the helix interfaces are
preserved to maintain possible interactions as in the wild-type protein.

Figure 3.5. WSA-LPPG Interactions. WSA structure is superimposed onto the TM domain of the GLIC
crystal structure. Residues showing cross-peaks with LPPG are highlighted in licorice representation in
cyan (for clarity no hydrogen atoms are displayed). Also displayed are lipid molecules co-crystallized
with GLIC (black). Notice that the intra-helix cavity between TM1 and TM4 for lipid binding is preserved
in WSA.
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In summary, the monomer structure of a water-soluble analogue of the Torpedo nAChR
1 subunit was resolved to the backbone RMSD of 0.69 ± 0.13 Å. The overall structure is
similar to the crystal structure of GLIC, demonstrating the robustness of the water
solubilization approach. The WSA structure preserved the anticipated intra-helical drug
binding site and lipid interaction site in the intact form of homologous receptors.
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4

Comparative Modeling of the Human

Opioid Receptor: A

Structural Context for Mutagenesis Studies and Agonist-Induced
Activation 1

4.1 Introduction
The study of opioids, their effects, and their interactions with opioid receptors [1,2] are
relevant to addiction, pain control and reward pathways [1,3,4]. Clinically, opioid receptors are
important in analgesia, euphoria, respiratory depression, feeding, hormone release, inhibition
of gastrointestinal transit, and anxiety [5,6]. To better understand the pharmacological activity
and diversity of the opioid receptors, it is desirable to have molecularly detailed structures that
aid in understanding their cellular responses to a variety of ligands. Such structural information
could also aid the rational design of new drugs. Until now, the structures of the opioid
receptors have not been obtained by experimental means, and therefore computational
models are of central importance. Herein comparative modeling is used to obtain models of
the

opioid receptor and better understand some of its functionally related properties.

1
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Opioid receptors are part of the largest family of integral transmembrane proteins
coded by the human genome, the G protein-coupled receptors (GPCRs) [7]. GPCRs mediate
most transmembrane signal transduction, usually in response to hormones, neurotransmitters
and environmental stimulants. Each GPCR comprises an extracellular N terminus, seventransmembrane (7TM) helical segments separated by alternating intracellular and extracellular
loop regions, and an intracellular C terminus [7-9]. Opioid receptors are part of the largest
GPCR family, family A (rhodopsin-like) [10], and other members include the receptors for
epinephrine, dopamine, serotonin, and adenosine [11].
The

opioid receptor is the primary receptor in the brain for endogenous opioid

neuropeptides as well as exogenously administrated opioid compounds [1,3,12]. Potent drugs
such as morphine, heroin, fentanyl and methadone induce their pharmacological effects
through the activation of this receptor [13].
The

opioid receptor structure has not yet been experimentally determined, and

indirect computational methods, including comparative modeling and de novo methods, have
been used to suggest structural details of this important signal transduction protein [14-19].
Comparative (homology) modeling provides three-dimensional information concerning protein
structures, particularly for proteins such as the

opioid receptor that are difficult to obtain

experimentally in large quantity for use in X-ray crystallography or protein NMR structural
studies [20,21]. The atomic-resolution structural information suggested from such models can
be used to interpret experimental data, predict the functional effects of different mutations,
motivate hypotheses concerning structure and function, and design medications [22].
In creating models of the opioid receptors, only the structure of bovine rhodopsin has
been used previously [15-17]. In recent years, several additional GPCR structures have been
solved to high resolution: the human

2

adrenergic receptor (2.4 Å) [23], the turkey

1

adrenergic receptor (2.7 Å) [24], and the human A2A adenosine receptor (2.6 Å) [25]. The use
of these additional GPCR structures may improve the quality of the models and be useful in
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formulating hypotheses and interpreting mutational data. The use of the structure of the

2

adrenergic receptor seems particularly appealing [23,26]. Although the sequence identity
between the human

opioid receptor and the human

compared to that with bovine rhodopsin (25%), the

2

adrenergic receptor is just (26%),

opioid receptor and

2

adrenergic

receptor may share similar interactions with their respective ligands since epinephrine is
structurally similar to opioids [1,27]. In addition, increasing the number of templates often
helps to improve the accuracy of comparative protein modeling [28,29]. Comparative models
created by using just one template emphasize the shortcomings of the modeling procedure by
heavily biasing the structures of the created models [23].
Herein models of the human

opioid receptor (hMOP-R) were constructed with

comparative modeling. Two families of structures were created: (a) one used structures of
human

2

adrenergic receptor and bovine rhodopsin as templates and (b) the other also

included the turkey

1

adrenergic receptor and the human A2A adenosine receptor as

templates. Representative structures of each of these two- and four-template ensembles were
considered in light of a large set of mutagenesis studies. The two- and four-template models
are very similar and may be used to interpret a variety of experimental data. Molecular
docking calculations were carried out on these models using an opioid antagonist (naloxone)
and an opioid agonist (morphine). The docking calculations are consistent with previously
proposed binding sites and suggest specific interactions of the opioid ligands with key
residues in the receptor. Using the proposed agonist-induced activation mechanisms of the
adrenergic receptors and the A2A adenosine receptor, residues involved in agonist recognition
of h-MOR-P are suggested.
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4.2 Methods
The approach taken to obtain models of hMOP-R involves alignment of the
sequences, creation of the comparative models, minimization, and structural evaluation.
Docking calculations were used to assess the models and potential protein-ligand interactions.

4.2.1 Sequence Alignment
The sequences of hMOP-R, human
1

2

adrenergic receptor, bovine rhodopsin, turkey

adrenergic receptor and human A2A adenosine receptor were obtained from the UniProt

Knowledgebase UniProtKB server with the accession numbers P35372, P07550, P02699,
P07700, and P29274, respectively [30].
Given the importance of sequence alignments in the comparative modeling procedure
[20,31,32], several different programs and substitution matrices were considered. BLASTp
[33], SIM [34], ClustalW [35], and Phyre [36] were used to align the sequences of hMOP-R
and human

2

adrenergic receptor. In the case of BLASTp, three members of the “Blosum”

substitution matrix family [37] (Blosum62, Blosum45 and Blosum80) and one member of the
“PAM” substitution matrix family [38] (PAM70) were used. For the case of the alignment tool
SIM, Blosum62 and Blosum30 were used. For ClustalW just the Blosum30 matrix was used.
The protein structure prediction server Phyre, was also utilized. Standard penalty gaps were
applied in all the cases [33-35]. A similar procedure was carried out in the case of hMOP-R
and bovine rhodopsin, hMOP-R and

1

adrenergic receptor, and hMOP-R and A2A adenosine

receptor.
A final sequence alignment was obtained for each pair of proteins and modifications
were performed to maintain highly conserved fingerprint residues of the rhodopsin-like GPCR
family [39]. Among these are: the disulfide bond between TM3 and the second extracellular
loop (EC2), the “DRY” motif in TM3, the XBBXXB motif in the third intracellular loop (IC3)
(where B represents a basic amino acid and X represents a non-basic residue, LRRITR in the
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case of hMOP-R), the FXXXWXPX[F] motif in TM6 (FIVCWTPIH in the case of hMOP-R), the
NPXXY motif in TM7 (NPVLY in hMOP-R), and the C-terminal cys palmitoylation site.[39] The
final multiple sequence alignment is presented in Figure 4.1.

Figure 4.1. Sequence Alignment Used in the Creation of the Models of the Human
Receptor, hMOP-R. The templates are: human

2

Opioid

adrenergic receptor (ADR 2) and bovine rhodopsin

(bRHO). The residues of the N- and C- terminus are excluded (residue 1 to 65 and residues 354 to 400,
respectively). Also, the residues excluded from the comparative modeling are colored in gray. The most
conserved residues at each of the transmembrane helices are depicted in blue. The secondary structure
of the

2

adrenergic receptor based on STRIDE [40], is shown below the sequences. Residue numbering

of hMOP-R is shown. Highly conserved motifs in the rhodopsin-like GPCR family are highlighted in
yellow.
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4.2.2 Comparative Modeling and Minimization
Two different ensembles of models of the hMOP-R were constructed. (i) The first
ensemble used the X-ray crystallographic structures of human

2

adrenergic receptor at 2.4 Å

resolution (PDB accession code: 2RH1) [23] and bovine rhodopsin at 2.2 Å resolution (PDB
accession code: 1U19) [41] as templates. (ii) In addition to these templates, the second
ensemble used the X-ray crystallographic structures of turkey

1

adrenergic receptor at 2.7 Å

resolution (PDB accession code: 2VT4) [24] and human A2A adenosine receptor at 2.6 Å
resolution (PDB accession code: 3EML) [25].
Using the sequence alignments and the two- and four-template structure sets
described above, one hundred independent models (from residue 65 to 353) were generated
using Modeller 9v2 with the refinement optimization level adjusted to slow [42,43]. The side
chains from the resulting models of the two-template and four-template ensembles, were
minimized using NAMD2 [44] and the CHARMM22 force field [45]. Hydrogen atoms were
added and minimization was performed by the conjugate-gradient method until the total
energy remains constant (change in energy less than 1.0 kcal/mol). Models with the lowest
energy were characterized using Molprobity [46] to confirm that no steric clashes or unusual
conformations of the backbone and side chains are present. The binding site cavities for the
models were calculated and analyzed with CASTp [47].

4.2.3 Docking Calculations
Naloxone (antagonist) and morphine (agonist) were docked into representative
models using DockingServer [48] (the DockingServer uses the AutoDock4 [49] algorithm for
the docking calculations). The geometries of naloxone and morphine were obtained from the
PubChem database (CID: 5284596 and 5288826, respectively) [50]. The geometry of the
ligands was optimized using the PM3 semiempirical method using MOPAC2009 [51], which
was also used to calculate the partial charges. The Lamarkian genetic algorithm was used
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during the docking calculations with the local search method developed by Solis and Wets
[52]. The initial position, orientation, and value of the torsion angles for the ligands were set
randomly. Default parameters for the genetic algorithm were used in all the calculations.

4.3 Results and Discussion
4.3.1 Template Structures
The four structural templates used for the creation of the hMOP-R belong to the same
family of hMOP-R (family A) and are among the most studied GPCR systems. Each receptor
comprises seven transmembrane helices that form a helical bundle. The helices are
connected by intracellular (IC) and extracellular (EC) loops.
The human

2

adrenergic receptor is part of the family A of GPCRs, particularly of the

amine group [23,26,53], and is the target of the catecholamine hormone epinephrine
(adrenaline). The structure contains a small helical segment perpendicular to the seven-helix
bundle. Helices TM2, TM4, TM5, TM6 and TM7 contain proline-induced kinks that are
believed to be relevant in the rearrangement needed for the activation of the G protein. An aneurysm is present in helix TM2, and the structure has an exposed loop (EC2) that forms a
helical segment.
Rhodopsin is composed of the protein opsin and the covalently bound cofactor retinal
[41]. Proline-induced kinks are located in helices TM1, TM4, TM6 and TM7. In contrast to the
second extracellular loop in
sheet structure. Similar to the
The turkey

1

2

adrenergic receptor, the EC2 loop forms a partially buried 2

adrenergic receptor, there is an -aneurysm present in TM2.

adrenergic receptor shares high similarity with the

2

adrenergic

receptor [24]. Structurally, one of the main differences is a helical motif located in the second
intracellular loop (IC2) that is absent in the structure of
in the structure of bovine rhodopsin.
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2

adrenergic receptor and also absent

The human A2A adenosine receptor endogenous ligand is the nucleoside adenosine
[25]. Proline-induced kinks are located in helices TM2, TM5, TM6 and TM7 and in addition to
the highly conserved disulfide bond, two extra disulfide bonds restrict the conformational
space of the EC2 loop. Similar to the

1

adrenergic receptor, a helical segment located in the

second intracellular loop (IC2) that is absent in the

2

adrenergic receptor and bovine

rhodopsin. The protein also contains an -aneurysm in TM2.
These four structures were used as templates in the comparative modeling procedure.
Two different sets of models of hMOP-R were created in order to test the hypothesis that more
templates produce better models. The first set contains an ensemble of structures obtained
using two templates, the

2

adrenergic receptor and bovine rhodopsin. The second set

contains an ensemble of structures generated using four templates:
bovine rhodopsin,

1

2

adrenergic receptor,

adrenergic receptor and A2A adenosine receptor. Importantly, in order to

isolate if significant differences exist with the introduction of more templates, the sequence
alignments used were exactly the same in both calculations. The conserved disulfide bond
was explicitly specified in the calculation. Special attention was paid to relax the
in TM2 present in all the templates and suggested to be absent in the

-aneurysm

opioid receptor [17].

Finally, the structures were refined by energy minimization (see Methods).

4.3.2

Opiod Receptor Mutagenesis Studies
Site-directed mutagenesis studies provide valuable molecular information and can be

compared with the comparative models. Although the human
widely studied, the rat and mouse

opioid receptor has been

opioid receptors are the more commonly used to probe

the impact of specific mutations. The sequence homology between human, rat and mouse
opioid receptors is high. For the human and rat

receptors, the sequence similarity is 94%

(376/400) for the entire sequence and 98% (285/288) for the transmembrane portion
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considered in the present study based on the pairwise alignment using BLASTp [33]. The
similarity of the human and mouse

receptors is 94% (376/400) for the entire sequence and

98% (284/288) for the transmembrane domain. Table 4.1 summarizes previous findings from
the mutational studies of the

opiod receptor, and Figures 4.2 and 4.3 illustrate some of the

residues involved in the mutagenesis studies as well as highly conserved residues in hMOPR.

4.3.3 Ensemble Structures
Figures 4.2a and 4.2b render the backbone root mean square deviation (rmsd) for
each residue. The calculation is done relative to the lowest energy structure and the average
is over models in each ensemble. In the case of four-template ensemble the range of rmsd
values is 0.12 to 7.07 Å with an average residue rmsd of 0.44 ± 0.68 Å while in the case of
two-template ensemble the range of values is 0.11 to 9.01 Å with an average residue rmsd of
0.53 ± 0.95 Å. As expected, the variability of the transmembrane region is small when
compared with that of the loops and the termini. Figures 4.2c and 4.2d show views of relevant
ligand-binding residues from the extracellular side of the four-template structure and the twotemplate structures, respectively. The average side chain rmsd value of all the residues in
Table 4.1 is 0.97 ± 0.64 Å for the four-template ensemble and 1.10 ± 0.55 Å for the twotemplate ensemble. In summary, including two additional templates (

1

adrenergic receptor

and A2A adenosine receptor) does not significantly change the ensemble results when the
same alignment is used.
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SEQUENCE
NUMBER IN
THE HMOP-R
D116 (2.50)
D149 (3.32)
Y150 (3.33)
N152 (3.35)
D166 (3.49)
S198 (4.54)
I200 (4.56)
N232 (5.36)
K235 (5.39)
T281 (6.34)
H299 (6.52)
K305 (6.58)
W320 (7.35)
H321 (7.36)
I324 (7.39)
Y328 (7.43)
S331 (7.46)
C142 (3.25)
C219 (EC2)
H225 (EC2)
E231 (EC2)
N88 (1.50)
D116 (2.50)
N334 (7.49)
K235 (5.39)
C237 (5.41)
I236 (5.40)
F239 (5.43)
H299 (6.52)
V302 (6.55)
F243 (5.47)
W295 (6.48)
K305 (6.58)
V318 (7.33)
W320 (7.35)
H321 (7.36)
N334 (7.49)
D116 (2.50)

DESCRIPTION
Mutation to A, N or Q reduced binding of DAMGO to less than 5% of WT. Also Mutation to N
reduces dramatically the affinities for a peptide agonist [54].
Site-directed mutagenesis studies indicated that it is involved in the primary binding site and also
that mutation to A and N diminishes the binding affinity to agonist and antagonist. Mutation to E
results in similar properties as the wildtype [54,55].
Mutation to F reduced the binding affinities to some selective agonists but did not alter the
affinities to DAMGO, naloxone and the non-selective opioids etorphine and buprenorphine [56].
Mutation to A produced a 20-fold increase in binding affinity for fentanyl but just a 10-fold increase
for morphine [57].
Mutation to H, Q, Y and M led to agonist independent activation [58,59].
Important not for ligand binding but most likely for maintaining the receptor conformation [60].
Mutation to V resulted in a four- to five-fold decrease affinity for agonists [57].
Mutations to T or L increased the potency of fentanyl and morphine [61].
Covalently labeled by -FNA, as suggested by site-directed mutagenesis studies [62].
Mutation to K at the junction of IC3 loop led to agonist activation [63].
Mutation to A decreases the ligand binding of and opioid receptors. Mutation to A reduces
binding to DAMGO and naloxone [64].
Mutation to E (to mimic receptor) produces activity similar to that of wildtype receptor for norBNI and GNTI ( receptor selective ligands) [65].
Mutation to A increases the binding affinities for the antagonists NTI and SIOM. Also, mutation to L
confers receptor-like potency for morphine [66,67].
Mutation to A reduces the binding affinities of opioid ligands but did not alter the affinities of
naloxone and bremazocine [56].
In receptor, mutation to T produces a significant reduction of the binding of dynorphin-related
peptides, indicating that this site is part of a key opioid peptide binding pocket [68].
Mutation to F decreases the binding affinity of naltrexone. Also this mutation decreases the K i value
of DAMGO by 20-fold [57].
Mutation to A decreases the potency of DAMGO. Together with other findings, it suggests
hydrophilic interactions between S331 and DAMGO [69].
Mutation of these cysteine residues suggests that the disulfide bond formed is critical for specific
ligand binding [70].
This position is critical for the receptor binding. Mutation to S decreases the affinity of bremazocine
25-fold [71].
Mutation to D increases binding affinity of an analogue of the peptide agonist JOM6 [72].
Mutagenesis studies suggested these highly conserved residues might be part of a hydrogenbonding network that ties together helices TM1, TM2 and TM3 [15,73].
These positions are the cross-linking sites for the reporter affinity label NNA, as suggested by
mutagenesis studies. [74].
2+

Based on engineered metal-binding sites (Zn ) it is suggested that I236 and F239 face the
binding-site crevice and form a metal-binding center with H299 and V302 [17].
Mutation experiments suggested that these residues might help to form the putative hydrophobic
pocket and constitute a general binding domain for opioids based of similarities with the opioid
receptor [75].
Mutational studies showed the importance of these third extracellular loop residues to differentiate
from opioid receptors [76].
Mutation N334D eliminated detectable binding of DAMGO, but an additional mutation of D116N
could partially restore the affinity, indicating a structural relation between these two residues [73].
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Table 4.1.

Opioid Receptor Mutagenesis Findings. The residue numbers used in the table are those

of hMOP-R. The numbering in parentheses is consistent with the Ballesteros and Weinstein indexing
system [77]: (number of the transmembrane helix).(residue number relative to most conserved residue in
transmembrane helix, which is assigned position 50). EC denotes extracellular loop; IC denotes
intracellular loop. -FNA and NNA are irreversible
2

4

opioid receptor ligands (reporter affinity labels).

5

DAMGO ([D-Ala ,MePhe ,Gly-ol ]enkephalin) is a synthetic opioid peptide having high specificity for
opioid receptor. NTI is the delta antagonist naltrindole, and SIOM is the delta antagonist 7’1

2

3

4

spiroindanooxymorphone. JOM6 (Tyr -c(S-Et-S)[D-Cys -Phe -D-Pen ]NH2) is a cyclic peptide agonist.

4.3.4 Model Structures of hMOP-R
The models with the lowest energy based on the CHARMM22 force field were
selected as representative of the four-template (4T-hMOP-R) and the two-template (2ThMOP-R) ensembles. These models of the hMOP-R consist of 288 amino acid residues
(residues 66 to 353) comprising the seven transmembrane helices with all the connecting
loops, plus the small helix that comes after the seventh transmembrane helix (residues 343352). N-terminal (residues 1-65) and C-terminal (residues 353-400) domains are not included
in the models. The structure of hMOP-R presents the typical counterclockwise arrangement of
the seven transmembrane helices (see Figures 4.2c, 4.2d, 4.3b and 4.3c). Proline-induced
kinks are located in helices TM2, TM4, TM5, TM6 and TM7. The EC2 loop forms a small
helical segment that is inherited from the structures of the adrenergic receptors and is
believed to be important in binding selectivity [1]. This loop is part of the entrance to the
putative opioid binding pocket and is constrained by a conserved disulfide bond between
residues C142 and C219. This extracellular segment is more extended when compared with
the comparable tightly packed loop of rhodopsin. The models present a helical segment in IC1
that is present in the all the templates but absent in the structure of bovine rhodopsin. The
TM2 in the hMOP-R models does not have the -aneurysm present in the templates [17].

55

Figure 4.2. Ensemble Structures of hMOP-R Using Four (a) and Two (b) Templates. The thickness
of the protein backbone chain and color is representative of the backbone rmsd value for each residue.
Subset of some of the residues from Table 4.1 for the 100 ensemble minimized structures for the fourtemplate (c) and two-template (d) ensemble, respectively. The average side chain rmsd of all the
residues in Table 1 is 0.97 ± 0.64 Å for the four-template ensemble and 1.10 ± 0.55 Å for the twotemplate ensemble.

Two different views of the model of hMOP-R are depicted in Figure 4.3a. In general,
4T-hMOP-R and 2T-hMOP-R are very similar with a backbone rmsd of 1.30 Å. One of the
most significant differences between the models is a helical segment in IC2 that is specific to
the

1

adrenergic receptor and A2A adenosine receptor; it is absent in 2T-hMOP-R (see inset

of Figure 4.3a). This loop connects helices TM3 and TM4 and is close to the important and
highly conserved DRY motif.
The secondary structures of the models were assigned with STRIDE [40], a
structurally base secondary structure method. The locations and lengths of the TM helices
were similar for both 4T-hMOP-R and 2T-hMOP-R.
Both models 4T-hMOP-R and 2T-hMOP-R can qualitatively aid the interpretation of
3.32

the experimental data collected in Table 4.1 (see Figures 4.3b and 4.3c). Asp149
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, known to

be crucial for binding affinity of agonists and antagonists [54,55], is located in TM3 and it is
directed toward the putative ligand-binding pocket. Lys235

5.39

is predicted to appear in this

binding site, where it could irreversibly bind the fumaramate moiety of the reporter affinity label
-funaltrexamine ( -FNA) [62]. The models contain a hydrogen-bonding network formed by
Asn88

1.50

, Asp116

2.50

and Asn334

7.49

, and interactions among these residues have been
5.47

suggested to tie TM1, TM2 and TM3 together [15,73]. Phe243

and Trp295

6.48

have been

suggested to form a hydrophobic pocket [75], observed in the models where these residues
appear near the interface between helices TM5 and TM6. The residue His299

6.52

is positioned

near both these residues in the putative binding site and is known to be important in agonist
affinity [64]. Position His225, in the EC2 loop, is located at the entrance of the binding pocket,
and this residue may interact with ligands; this position is critical for the receptor binding [71].
Mutation of Asp166

3.49

or Thr281

[58,63]. Residue Asp166

3.49

to Arg167

3.50

2.39

leads to an agonist-independent activation of the receptor

is part of the conserved triplet of residues, the DRY motif. In the

case of 4T-hMOP-R, Asp166
(4.1 Å), and Thr105

6.34

3.49

is in proximity to Arg181(IC2) (distance of 2.7 Å), Tyr108

(5.5 Å) (see Figure 4.3d). In the case of 2T-hMOP-R, Asp166

3.49

2.42

is near

(2.7 Å), and is part of a polar network together with Arg181(IC2), Asp179(IC2),

and to a less extent with Tyr108

2.42

(see Figure 4.3e). (The distances in parentheses are the

shortest distances between atoms in the different residue side chains.)
The importance of residue Thr281

6.34

in hMOP-R seems to be related with the region

denominated “ionic lock” [78]: the highly conserved Arg167

3.50

on TM3 together with a Glu

6.30

residue on TM6 has been proposed to be relevant to the stability of the inactive-state
conformation and therefore with the basal activity of different GPCRs [7,79]. In the case of the
X-ray crystallographic structure of the inactive state of rhodopsin [41], Arg
bridge with Glu

3.50

forms a salt

6.30

. Surprisingly, in the case of both adrenergic receptors [23,24] and the

adenosine receptor [25], the salt bridge between Arg
contains the highly conserved Arg

3.50

3.50

and Glu

on TM3 but it contains a Leu
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6.30

6.30

is disrupted. hMOP-R

residue in the analogous

position on TM6. In the case of 4T-hMOP-R, Arg167
residue Thr281
Arg167

3.50

6.34

3.50

is predicted to be in the vicinity of

(2.9 Å), that is, one turn in the helix separated from Leu277

is also close to the carbonyl group of Leu277

The position of Arg167

3.50

6.30

(3.0 Å), and to Thr105

2.39

2.39

3.50

(4.9 Å).

is closer to Asp166

3.49

6.34

(3.6 Å), and the carbonyl group of Ala177(IC2) (4.1 Å) than to Thr281

as seen in the case of 4T-hMOP-R. The position of Arg167
analogous Arg

3.50

(i+4).

in 4T-hMOP-R resembles more the position of the equivalent Arg

in rhodopsin. In the case of 2T-hMOP-R, the position of Arg167
Å), Thr105

6.30

3.50

(2.7

(5.9 Å)

in 2T-hMOP-R resembles the

in the adrenergic receptors and the adenosine receptor structures.
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3.50
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Figure 4.3. Alignment and Comparison of Representative Models of hMOP-R. (a) the representative
models from the four-template ensemble (4T-hMOP-R) and two-template ensemble (2T-hMOP-R) are
color in green and yellow, respectively. The most conserved residues at each of the transmembrane
helices are depicted as blue sticks. The highly conserved motifs in the rhodopsin-like GPCR family are
depicted as orange sticks; disulfide bond between TM3 and EC2, DRY in TM3, XBBXXB in IC3 (where B
represents a basic amino acid and X represents a non-basic residue), FXXXWXPX[F] in TM6, the
NPXXY in TM7 and the C-terminal cys palmitoylation site. The inset at the bottom shows one of the
most significant differences between the two models. The IC2 loop that connects helices TM3 and TM4
in the 4T-hMOP-R model, forms a helical motif inherit from the

1

adrenergic receptor and the A2A

adenosine receptor templates. (b) (c) Top views of the binding site for the 4T-hMOP-R and 2T-hMOP-R
models with a subset of the relevant residues involved in experimental studies (see Table 4.1). Side
chain residues are colored in magenta in both cases. This view of the hMOP-R from the extracellular
side of the membrane shows the counterclockwise arrangement of the TM helices. (d) (e), Views of the
TM3-IC2-TM4 region with the DRY motif for 4T-hMOP-R and 2T-hMOP-R, respectively. Asp166
and Tyr168

3.51

(Y) are colored in orange while Arg167

3.50

3.49

(D)

(R) is colored in blue.

A graphical summary (snake-like plot) of the features of 4T-hMOP-R is shown in
Figure 4.4. The lipid membrane region for the h-MOP-R is also shown and is identified using
the positioning of the

2

adrenergic receptor presented in the Orientation of Proteins in

Membrane Database [80]. Highly conserved positions, conserved motifs in the rhodopsin-like
family, positions involved in experimental studies, length of each of the helices and complete
sequence of hMOP-R, are also depicted.
Within the models, CASTp identified a putative binding cavity using a probe with a
3

radius of 1.4 Å. The calculated volume for 4T-hMOP-R is 1402 Å and for 2T-hMOP-R is 1717
3

Å . By comparison, the respective cavity volumes of

2

adrenergic receptor and bovine

3

rhodopsin are 2057.3 and 674.4 Å .
The quality of the models was examined with Molprobity. The Ramachandran analysis
for 4T-hMOP-R found one outlier, Thr313 located at the EC3 loop. The clashscore for all-atom
th

contacts was 6.35 (within the 89 percentile). In the case of 2T-hMOP-R, the Ramachandran
analysis identified three outliers, Pro226 in EC2, Met226 in IC3, and Thr317
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7.32

at the

th

beginning of TM7. The clashscore for all-atom contacts was 10.17 (within the 70 percentile).
th

As a reference, the clashscores for all-atoms for the templates are: 6.10 (90 percentile) for
th

th

adrenergic, 43.86 (6 percentile) for bovine rhodopsin, 19.05 (35 percentile) for
and 11.17 (66

th

1

2

adrenergic

percentile) for A2A adenosine receptors. The number of outliers in the

Ramachandran analysis for the four templates is zero, eight, one and zero, respectively.

Figure 4.4. Snake-like Plot of the Entire Sequence of hMOP-R. The glycosylation sites are those
proposed at UniProtKB [30]. The most conserved residues at each of the transmembrane helices are in
blue circles with the respective Ballesteros and Weinstein indexing number. Positions involved in
experimental studies mentioned in Table 4.1 are colored in magenta. The conserved motifs in the
rhodopsin-like GPCR family are colored in orange. Disulfide bond between C142 and C219 is indicated.
The N- and C- helical termini of each of the seven helices are depicted as bold circles. The membrane
region is colored in gray and was obtained by aligning the 4T-hMOP-R model to the structure of the

2

adrenergic receptor positioned in a membrane at the Orientation of Proteins in Membrane Database [80].
The absent (nonmodeled) sequence region in the model is display in gray circles.
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4.3.5 Comparison with Previous Opioid Models
Three previously published models of the inactive conformation were compared with
4T-hMOP-R and 2T-hMOP-R. i) The human

opioid receptor proposed by Kieffer and

coworkers (Model_A) [81], ii) the model of human
and coworkers (Model_B) [15], and iii) the rat

opioid receptor developed by Ferguson

opioid receptor model developed by Mosberg

and coworkers (Model_C) [17]. There is a fourth model of the human

opioid receptor but the

coordinates are not available [19].
Model_A is based on the structure of bovine rhodopsin (PDB accession code: 1F88)
and lacks the EC2 loop, which is important for ligand selectivity. The model contains the

-

aneurysm in TM2 and therefore residue Thr122 is highly exposed to the lipid membrane. The
3

volume for the binding cavity using CASTp with a radius probe of 1.4 Å was 1219.6 Å . The
main differences between this model and 4T-hMOP-R and 2T-hMOP-R are the positions of
the beginning of TM1 relative to the rest of the bundle, the presence of an -aneurysm in TM2
and finally, the absence of the second extracellular loop EC2.
Model_B is based on electron cryomicroscopy data[82] and the C

coordinate

template developed by Baldwin et al. [83] This model comprises only the seven
transmembrane helices. The TM2 helix does not contain the -aneurysm. The main difference
between this model and the 4T-hMOP-R and 2T-hMOP-R models is the presence of all the
connecting loops in our models of hMOP-R, which are fundamental to address the
receptor/ligand interactions.
Model_C is based on the structure of bovine rhodopsin (PDB accession code: 1GZM)
and was refined using experimentally determined structural-distance constraints [17]. This
model contains all the connecting loops, especially the important EC2 loop that forms a sheet structure and is buried in a similar way as the EC2 in bovine rhodopsin. In contrast, the
4T-hMOP-R and 2T-hMOP-R models have an EC2 loop that resembles the short helical
segment present in the adrenergic receptors. This extracellular region adopts a more

62

protruded position in comparison with the tightly packed loop of rhodopsin, leaving the entrace
of the putative binding site directly exposed to water. Similar to Model_B, Model_C does not
contain the
Tyr77

-aneurysm in TM2 and the first segment of the TM1 (residues Ser66

1.28

to

1.39

) is relatively closer to the rest of the helical bundle when compared with 4T-hMOP-R

and 2T-hMOP-R. The volume for the binding cavity using CASTp with a radius probe of 1.4 Å
3

was 1382.8 Å .
The models presented here (4T-hMOP-R and 2T-hMOP-R) provide information about
the extracellular regions of the hMOP-R, in particular the structure of the EC2 loop. Only
Model_C provides a structure of this important segment that is believed to be important for
ligand affinity, selectivity and functional differences between hMOP-R and other receptors
[1,7]. Model_C predicts an EC2 loop forming a short -sheet structure that protects the ligandbinding pocket from solvent access as the EC2 does in rhodopsin. In the case of hMOP-R,
and all the other available GPCR structures except rhodopsin, the endogenous ligands are
diffusible and noncovalently bound. The structures of the EC2 loop display a more open
binding site in comparison with rhodopsin, allowing access to the ligand-binding pocket.
The models presented here display significant improvements in the understanding of
the structure of the hMOP-R when compared with the previously published models. They are
able to aid in the interpretation of all the experimental data collected in Table 4.1. The models
contain information about the extracellular loop (EC2) that connects helices TM4 and TM5,
and the proposed structure for the EC2 loop is consistent with the experimental data [70-72].
In addition, the EC2 loop structure is consistent with the observation that other available
GPCR structures having diffusible endogenous ligands present a more protruded structure
when compared with that of rhodopsin allowing easier access to the ligand binding site [2325].
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4.3.6 Docking Calculations
Opioid ligands were computationally docked into the model structures. The crystal
structure of

2

adrenergic receptor [23],

1

adrenergic receptor [24], and A2A adenosine

receptor [25] were solved with diffusible antagonists (partial inverse agonists in the case of
2),

while the structure of the bovine rhodopsin was solved with the covalently bound cofactor

retinal in its 11-cis configuration [41], that is, all templates were solved in the inactive
conformation. For this reason, an opioid antagonist (naloxone) was primarily utilized in the
docking calculations to the

opiod receptor models. Naloxone has high affinity for the

opioid

receptor and contains a positively charged nitrogen atom that is thought to strongly interact
with the opioid receptor [6]. A classic opioid agonist, morphine, with a similar structure was
also considered.
To test the reliability of the docking results, the four ligands in each of the template
structures were docked into their corresponding receptors. In each case, the top docking
results were in aggrement with the crystal structure even in the case of larger and more
flexible ligands such as retinal and ZMA241385. The rmsd values between the
crystallographic ligand positions and the docking results for the heavy atoms are: carazolol
1.49 Å, retinal 1.41 Å, cyanopindolol 0.83 Å and ZMA241385 2.69 Å.
Due to the lack of flexibility intrinsic in the docking calculations used here,
modifications in the conformation of some side chains were needed to dock naloxone into 4ThMOP-R and 2T-hMOP-R. Specifically, these involve changes in some dihedral angles of
large residues such as Ile146, Tyr150, Trp228, Trp320, Ile324, and Tyr328 in the putative
binding pocket. For instance, in the case of Trp228 the dihedral angle ( ) between N-C -C -C
was modified by 3.5° (from a value of -50.5° to 54.0°). All the structures were docked in a
similar binding pocket as illustrated in Figure 4.5a. The binding site is located mainly between
helices TM2, TM3, TM6 and TM7 with small involvement of TM5.
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One of the docking results orients the positively charged ammonium nitrogen of
naloxone in proximity to Asp149
opioid ligands with Asp149

3.32

3.32

in helix TM3 (Figure 4.5b and 4.5c). The interaction of

has been found to be crucial for binding, and the mutation of

this position leads to a substantial decrease in binding affinity [55,84]. Furthermore, the two
adrenergic receptors have an aspartic acid located in an equivalent position (Asp113
the

2

and Asp121

3.32

for the

1).

In the crystal structure of

2

and

1

3.32

for

adrenergic receptors,

both ligands (carazolol and cyanopindolol, respectively) contain a positively charged nitrogen
atom interacting with this acidic residue. Figure 4.5d and 4.5e show a structural alignment of
2

adrenergic receptor and carazolol (cyan) with the hMOP-R models and naloxone (gray and

purple), where the positions of the positively charged nitrogens in carazolol and naloxone are
similarly located. When the crystal structure of

1

adrenergic receptor is used in the

comparison, similar relative positioning of ligand’s nitrogen atom is observed. The same
models were used to dock the opioid agonist morphine. In both cases, morphine is positioned
in the same binding cavity as naloxone, with orientations that bring the ammonium nitrogen of
morphine in proximity to the acidic residue Asp149

65

3.32

.

Figure 4.5. Docking Calculation Results for the Model Structures of hMOP-R. (a) Aligned structures
of the 4T-hMOP-R (green) and 2T-hMOP-R (yellow) models with the top docked structures. The ligand
molecules naloxone and morphine are located in the same binding site. The docked structures in the 4ThMOP-R model are colored in grey while the docked structures in the 2T-hMOP-R model are colored in
purple. (b) (c) Docked structure (naloxone) in a position that orients the positively charged nitrogen atom
close to the oxygen atoms of the acidic residue Asp149

3.32

(see dashed red line) for (b) 4T-hMOP-R and

(c) 2T-hMOP-R. d, e, Superposition of crystal structure of

adrenergic receptor with carazolol (cyan)

2

with the (d) 4T-hMOP-R and (e) 2T-hMOP-R models. Carazolol’s ammonium nitrogen atom (black circle)
that interacts with residue Asp113

3.32

that is analogous to Asp149

3.32

in hMOP-R.

4.3.7 Residues Involved in Agonist/Antagonist Ligand Binding
Based on recent findings involving GPCR agonist-induced activation mechanisms [8589], the hMOP-R models may be helpful in understanding the activation process of this
receptor. Based on comparisons of recent structures of GPCRs bound to agonist and partial
agonist [85-89], with their counterparts bound to antagonists and inverse agonists [23-25],
residues have been identified to interact particularly with agonist and proposed to be important
in agonist-induced activation.
In the case of the adrenergic receptors,

1

and

2,

the important residues involved in

agonist activation are located in TM5 [85,87]. Residues Ser211

5.42

and Ser215

5.46

form

hydrogen bonds with both full and partial agonists, but just the full agonists interact with
Ser215

5.46

. The equivalent position of h-MOP-R contains an alanine residue Ala242

5.46

.

In the case of the A2A adenosine receptor, the residues involved in direct interaction
with agonists and not with inverse agonists are located mainly in TM3 and TM7 [88,89].
Agonists formed non-polar interactions with Val84
interactions with Ser277

7.42

and His278

3.32

, Leu85

3.33

and Thr88

3.36

and polar

7.43

. Both kinds of interactions were concluded to be

important in the activation of the A2A adenosine receptor [88,89].
The general receptor structural changes upon agonist-induced activation were
concluded to be: i) The inward motion of TM3, TM5 and TM7 (contraction of the binding
pocket), and ii) the formation of a bulge in TM5 (centered around Ser215
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5.46

and Ser207

5.46

in

1

and

adrenergic receptors, and Cys185

2

5.46

in the adenosine receptor) [89]. Finally, based

on structural alignments, it was concluded that the positions involved in contact with agonist in
the complexes

1 adrenergic

Asp121

3.32

, Val84

Asn310

6.55

, Asn253

receptor/isoprenaline and A2A adenosine receptor/adenosine are:

3.32

; Val125

3.36

6.55

, Thr88

; Phe307

6.52

3.36

, His250

; Ser211

6.52

5.42

, Asn181

; Asn329

7.39

, Ile274

5.42

; Phe306

7.39

6.51

, Leu249

and Tyr333

7.43

, His278

respectively (see Figure 4.6a) [89]. Using the representative models of the human
receptor, 4T-hMOP-R and 2T-hMOP-R, the equivalent positions are Asp149
Val238

5.42

, Ile298

6.51

, Val302

6.55

, His299

6.52

, Ile324

7.39

have been studies on hMOP-R involving Asp149
Tyr328

and Tyr328

3.32

7.43

, Val302

;

7.43

,

opioid

3.32

, Met153

3.36

,

7.43

. To our knowledge, there

6.55

, His299

3.36

. The effects of mutations involving residues Met153

6.51

6.52

, Val238

, Ile324

5.42

7.39

and

, and Ile298

6.51

have yet to be explored, however, particularly with regard to agonist-induced activation in
opioid receptor, and would be interesting candidates for future studies.

Figure 4.6. Residues Involve in Agonist-Induced Activation of hMOP-R. (a) Equivalent positions in
the hMOP-R that make contacts with agonists in the complexes A2A adenosine receptor/adenosine and
1

adrenergic receptor/isoprenaline (cyan space-filling models).[89] To our knowledge, positions

Met153

3.36

, Val238

5.42

binding. (b) Ala242

, and Ile298

5.46

6.51

have not been investigated to address their relevance in agonist

is centered in the bulge formation upon agonist binding. (c) The interface of TM5

and TM6 is formed mostly by hydrophobic interactions. In order to reinforce the interaction of TM5 and
TM6, mutation of position Thr296

6.44

for a more hydrophobic residue is anticipated to have similar effects
5.43

as the hydrogen bond formation between Ser

and Asn

67

6.55

in the agonist bound adrenergic receptors.

From

these

previous

structural

studies

of

the

adenosine/agonist

and

adrenergic/agonist complexes and the structural information from the 4T-hMOP-R and the 2ThMOP-R models, two main predictions for the hMOP-R are suggested:
1) Given the bulge formation in TM5 upon agonist binding and the thermostabilizing mutations
in the A2A adenosine receptor, there may be an important interaction between positions
Cys185

5.46
85

binding.

and Gln89

3.37

[88,89]. These positions have been shown to be relevant to agonist
85

The mutation Q89A stabilizes the active state of the A2A adenosine receptor,

so

disruption of the interaction at this position in hMOP-R is suggested to be also relevant (the
equivalent positions in h-MOP-R are Ala242

5.46

the models of h-MOP-R, mutation of Ala242

and Phe154

5.46

3.37

, see Figure 4.6b). Based on

could have significant implications in the

activation of the receptor, Moreover, position Ile200

4.56

also seems to play an important role in

these interactions (see Figure 4.6b). Mutagenesis of this position for a smaller residue I200V,
decreases the agonist affinity (Kd) of morphine and the synthetic opioid peptide DAMGO by a
factor of 4 to 5 [57]. Using the models proposed here, the explanation for this result is that a
5.46

smaller residue reduces the propensity toward inward movement of residue Ala242

(center

of the bulge formation upon agonist binding), thus we anticipate that a bulkier residue would
facilitate the inward movement of Ala242

5.46

, shifting the equilibrium to the active state and

therefore increasing agonist binding affinity.
2) Upon binding of agonists in the case of the adrenergic receptors, there is a formation of a
hydrogen bond (Ser212

5.43

and Asn310

6.55

in

1,

Ser204

5.43

and Asn293

6.55

in

2)

between

helices TM5 and TM6. In the case of hMOP-R, the residue identities at these positions
(Phe239

5.43

and Val302

6.55

) prevent similar hydrogen binding interactions. If the reinforcement

of the interactions of helices TM5 and TM6 occurs upon agonist binding, using the models
presented here, mutation of Thr296

6.44

for a more hydrophobic residue could strengthen the

interactions of TM5 and TM6 in a similar fashion to that observed in the
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1

( 2) adrenergic

receptors. As a result, a shift in the equilibrium to active conformations and an increase in
agonist binding would be expected (see Figure 4.6c).

4.4 Conclusions
Models of the human

opioid receptor have been created that leverage new

structural data concerning GPCRs. We compare varying the number of templates used in the
comparative modeling. Interestingly, the ensemble analysis showed that there is small
difference when four templates and two templates are used to create the models. One of the
main conclusions is that both ensembles produced similar results on the condition that the
sequence alignment used is the same. More templates usually produce better sequence
coverage and therefore the hypothesis that more templates are able to improve the
comparative models is still reasonable. We have seen from the different GPCR structures
available that they have some structural diversity and therefore surmount some of the
structural bias inherent in using just one structure. Nonetheless, the structures used in this
study are still limited to the four mentioned herein.
Based on the energies after minimization, two models were selected as representative
of each ensemble. Detailed analysis of 4T-hMOP-R and 2T-hMOP-R shows that the two
models are similar and that both may be used to interpret the collected experimental data.
One important difference is the second intracellular loop (IC2) that connects TM3 and TM4.
For this segment, 4T-hMOP-R forms a helical motif that is inherited from the

1

adrenergic

receptor and the A2A adenosine receptor and therefore is absent in the 2T-hMOP-R model.
This region of the receptor is relevant because it is close to the highly conserved DRY motif.
The docking calculations were in aggrement with some experimental data and they
show a possible binding orientation of the ligand. Also, both models produce similar results for
the docking of an antagonist and an agonist. Naloxone, an opioid antagonist, was docked into
4T-hMOP-R and 2T-hMOP-R. One particular docking result, oriented the positively charged
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nitrogen of naloxone, close to the acidic residue Asp149

3.32

located in helix TM3. This residue

has been shown to be crucial for the binding of different ligands. The crystal structures of
and

1

adrenergic receptors show that the analogous residue Asp

3.32

2

is interacting with a

positively charged nitrogen atom from carazolol and cyanopindolol, respectively. When the
structures of 4T-hMOP-R/naloxone and 2T-hMOP-R/naloxone are superimposed with the
structure of

2

adrenergic/carazolol and

1

adrenergic receptor/cyanopindolol, the positions of

the positively charged nitrogens are almost identical. The opioid agonist morphine was docked
in the models and binds in the same binding cavity as naloxone, with the positively charged
nitrogen of morphine close the residue Asp149

3.32

. Based on information from GPCRs agonist

bound structures and the suggested agonist-induced mechanisms, predictions about residues
involved in the agonist-induced activation process in the hMOP-R are anticipated. Specifically,
the following is proposed. (1) A substitution that facilitates the inward movement of TM5 and
the bulge formation centered at Ala242
residue at position Ile200

5.46

. The mutation involves interaction with a bulkier

4.56

. (2) A single mutation to strengthen the interactions between TM5

and TM6 in hMOP-R, based on the suggested reinforced interactions upon agonist binding
between TM5 and TM6. The substitution involves a hydrophobic residue at position Thr296

6.44

.
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5

Computational Protein Design and Molecular Dynamics

Simulations of Stromal Cell–Derived Factor–1

and Simplified Peptide

Analogs1

5.1 Computational Protein Design to Re-Engineer Stromal Cell–Derived Factor–1
Generates an Effective and Translatable Angiogenic Polypeptide Analog

2

5.1.1 Introduction
More people die annually of cardiovascular disease than of any other cause. The
World Health Organization estimates that more than 17 million people per year die of
cardiovascular disease. Of these deaths, an estimated 7.2 million were due to ischemic heart
disease. An estimated 80 000 000 American adults (approximately 1 in 3) have at least 1 type
of cardiovascular disease, with more than 22 000 000 having either coronary heart disease or
heart failure [1].

1

This project was a collaboration with the group of Professor Y. Joseph Woo at Division of
Cardiovascular Surgery, Department of Surgery, University of Pennsylvania School of
Medicine, Philadelphia, PA 19104.
2
Adapted in part from William Hiesinger, Jose Manuel Perez-Aguilar, Pavan Atluri, Nicole A.
Marotta, John R. Frederick, J. Raymond Fitzpatrick III, Ryan C. McCormick, Jeffrey R.
Muenzer, Elaine C. Yang, Rebecca D. Levit, Li-Jun Yuan, John W. MacArthur, Jeffery G.
Saven, Y. Joseph Woo Circulation 2011, 124:S18-26.
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Treatments for ischemic heart disease often fail because they do not address the
underlying ventricular cellular pathophysiology and, most importantly, do not restore
microvascular perfusion, which has been shown to be a critical, independent predictor of
ventricular remodeling, as well as reinfarction, heart failure, and death [2,3]. On the other
hand, postinfarction patients who develop robust angiographic collateralization manifest
improved regional ventricular function, which suggests an important role for the native
revascularization process [4]. Current therapeutic options for ischemic heart disease are only
capable of intervening in relatively large arteries, which leaves pervasive microvascular
dysfunction unaddressed. This is important because microvascular integrity, specifically
microvascular blood velocity and flow, predicts functional recovery of ischemic myocardium [59].
In addition, current interventions are instituted relatively late in the overall time course
of the disease process, with macrorevascularization possible in only 63% to 80% of patients
with ischemic heart disease [10]. Even with reestablishment of epicardial coronary artery flow
through thrombolysis, percutaneous intervention, or bypass grafting, a paucity of patent,
functional microvasculature remains. Angiogenic cytokine therapy is a microrevascularization
strategy that can serve as a primary therapy at any point in the disease process and can be
used synergistically with traditional coronary revascularization methods [11]. A wide variety of
cytokines and microrevascularization techniques have been used with varying degrees of
success [12-15].
Stromal cell–derived factor–1 (SDF) is a powerful chemoattractant and is considered
to be one of the key regulators of hematopoietic stem cell trafficking between the peripheral
circulation and bone marrow. It has been shown to effect proliferation and mobilization of
endothelial progenitor cells (EPCs) to induce vasculogenesis and is significantly upregulated
in response to both myocardial ischemia and infarction [16,17]. SDF, a 67–amino acid protein,
is also remarkably conserved among species; a single amino acid substitution is all that
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differentiates the human and murine sequences [18]. Experimentally, delivery of SDF to
ischemic myocardium has been shown to increase circulating EPCs, significantly enhance
myocardial EPC density, increase vasculogenesis, and augment myocardial function by
enhancing perfusion, reversing cellular ischemia, increasing cardiomyocyte viability, and
preserving ventricular geometry [19,20].
However, exogenous SDF is quickly degraded by multiple proteases [18,21], has a
large and complex tertiary structure that involves multiple disulfide linkages [22], and is very
expensive because it is a recombinant protein. Smaller analogs of SDF may provide
translational advantages, including enhanced stability and function, ease of synthesis, lower
cost, and potential modulated delivery via engineered biomaterials [23,24]. In the present
study, we set out to design and engineer a minimized, highly efficient polypeptide analog of
the SDF molecule using computational molecular modeling and design. The primary design
goal was to remove the large, central

-sheet region and link the native N–terminus

(responsible for receptor activation and binding) and the C–terminus (responsible for
extracellular stabilization) while maintaining functionality and the approximately perpendicular
orientation between the 2 termini [22]. Two disulfide bonds located in the large central -sheet
region help to maintain the conformation of native SDF. To recover a similar conformation
after excision of this portion of the protein, proline residue linkers were considered to connect
the N– and C–termini. The cyclic proline residue limits the conformational space accessible to
the polypeptide. Loop modeling calculations revealed the variability of conformations explored
by linkers comprising different numbers of proline residues. A designed diproline linker yielded
energetic and conformational advantages that resulted in a small, low-molecular-weight
engineered SDF polypeptide analog (ESA) that was shown to have activity comparable to or
better than recombinant human SDF both in vitro and in a murine model of ischemic heart
failure.
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5.1.2 Methods
5.1.2.1 Computational Protein Design, Modeling, and Synthesis
Loop modeling calculations were performed with the program MODELLER, which
implements a loop modeling algorithm that consists of an optimization of a defined segment of
protein structure in a fixed environment, guided by a pseudo–energy-scoring function [25].
Fifty different structures for a 1-, 2-, and 3-proline residue linker were created while
constraining the coordinates of the remainder of the protein. The conformation with the lowest
effective energy (best score) was analyzed with MolProbity, which provides detailed all-atom
contact analysis of steric interactions, dihedral angles, and possible hydrogen bonds and van
der Waals contacts [26]. After the amino acid sequence of the newly designed ESA peptide
had been computationally designed and analyzed, it was synthesized by solid-phase peptide
synthesis, which involves the incorporation of N

-amino acids into a peptide of any desired

sequence with 1 end of the sequence remaining attached to a solid support matrix. After the
desired sequence of amino acids has been obtained, the peptide is removed from the
polymeric support.

5.1.2.2 Cell Isolation
Bone marrow mononuclear cells were isolated from the long bones of adult male
green fluorescent protein (GFP)-expressing Wistar rats by density-gradient centrifugation with
Histopaque 1083 (Sigma-Aldrich) and cultured in endothelial basal medium-2 supplemented
with EGM-2 SingleQuot (Lonza) containing human epidermal growth factor, FBS, vascular
endothelial growth factor, basic human fibroblast growth factor, recombinant human long R3
insulin-like growth factor-1, ascorbic acid, heparin, gentamicin, and amphotericin-B. The
combination of endothelium-specific media and the removal of nonadherent bone marrow
mononuclear cells was intended to select for the EPC phenotype.
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5.1.2.3 Functional Characterization of Isolated EPCs by Boyden Chamber Assay
Boyden chambers (Neuro Probe) were used to assess EPC migration. Briefly, 8- m
filters were loaded into control and experimental chambers. Fourteen-day EPCs cultured in
endothelium-specific media on vitronectin-coated plates were trypsinized, counted, and
brought to a concentration of 90 cells/ L in Dulbecco phosphate buffered saline (DPBS). The
bottom chamber of the control and experimental chambers were loaded with DPBS, 100
ng/mL recombinant SDF (R&D Systems) in DPBS, or 100 ng/mL ESA in DPBS. A 560- L cell
suspension was added to the top chamber of each. All 3 chambers were incubated at 37°C,
5% CO2 for 4 hours. The cells remaining in the top chamber were wiped clean with a cotton
swab, and the filter was removed. Slides were visualized on a DF5000B Leica Fluorescent
scope and analyzed via LASAF version 2.0.2 (Leica) software. Boyden chamber analysis was
performed in triplicate. Additional Boyden chamber assays were run to generate a doseresponse curve to compare molar equivalents of ESA and SDF. A series of progressively
increasing ESA and SDF gradients (0.625, 1.25, 2.5, 5, 12.5, 20, 25, and 50 nmol/L) were
used, and assays at each dose were run 10 times.

5.1.2.4 CXCR4 Receptor Activation Assay
Fourteen-day EPCs cultured in endothelium-specific media on vitronectin-coated
plates were trypsinized and plated onto the bottom of a 96-well cell culture plate at a density of
10 000 cells per well and allowed to adhere for 24 hours. Cells were incubated with culture
media that contained recombinant SDF (0.5

g/mL) or ESA (0.5

g/mL) or media only

(control) for 10 minutes and subsequently were fixed in 4% formaldehyde. Phosphorylated
and total AKT levels were quantified with the FACE AKT ELISA kit (Active Motif). These
experiments were also repeated but with the addition of the chemokine receptor 4 (CXCR4)
receptor antagonist AMD3100 to each experimental group. Results are reported in optical
density (OD) units.
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5.1.2.5 CXCR4 Receptor Expression
EPCs were seeded overnight at a density of 1 104 cells per coverslip in 4-well slide
chambers. Cells were either treated with 100 ng/mL SDF or 100 ng/mL ESA at 37°C for 6
hours. After chemokine stimulation, the cells were fixed and immunostained with rabbit antiCXCR4 antibody (Abcam) at 1:250 for 12 hours. Cells were then incubated with Alexa 488
donkey anti-rabbit polyclonal antibody (Invitrogen) at 1:250 for 1 hour at room temperature.
The cells were counterstained with DAPI to visualize nuclei. Immunofluorescence images
were acquired with Zeiss ZEN 2010 software and a Zeiss LSM 710 confocal laser
fluorescence scanning microscope.

5.1.2.6 Animal Care and Biosafety
Male CD-1 mice weighing 25 to 30 g were obtained from Charles River. Food and
water were provided ad libitum. This investigation conformed with the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes of Health (NIH publication
No. 85-23, revised 1996) and was approved by the Institutional Animal Use and Care
Committee of the University of Pennsylvania (protocol #709026).

5.1.2.7 Ischemic Cardiomyopathy Model
Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg), intubated
with a 22-gauge catheter, and mechanically ventilated (Hallowell EMC). With the animal
supine, an anterior thoracotomy was performed in the left fourth intercostal space, and an 8-0
polypropylene suture was placed around the mid left anterior descending coronary artery
(LAD) midway between the left atrial appendage and left ventricular (LV) apex and ligated to
produce a large anterolateral myocardial infarction of 30% of the LV. The extent of infarction is
highly reproducible in our hands, and progression to cardiomyopathy has been well
documented. After ligation, animals were randomly assigned to receive direct intramyocardial
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injection into the peri-infarct border zone of either saline (30 L, n=7), SDF (6 g/kg in 30 L,
n=13), or ESA (6 g/kg in 30 L, n=10). The thoracotomy was then closed, and the animals
were extubated and recovered. Buprenorphine (0.5 mg/kg) was administered for postoperative
analgesia. Both treatment groups received subcutaneous injections of 40

g/kg liquid

sargramostim (granulocyte-macrophage colony-stimulating factor), diluted in saline for a total
volume of 100 L, immediately postoperatively and on postoperative day 1.

5.1.2.8 In Vivo Angiogenic Growth Factor Expression
To assess upregulation of angiogenic growth factors and evaluate any potential
sustained angiogenic effect of ESA treatment, hearts from all animals (control n=7, SDF n=13,
and ESA n=10) were explanted 2 weeks after LAD ligation, and myocardial tissue biopsy
samples were taken from the ischemic border zone. Samples were homogenized in T-Per
tissue extraction reagent (Thermo-Fischer), normalized for total protein content via a Quick
Start Bradford Protein Assay (Bio-Rad Laboratories), and tested for presence of mouse
angiopoietin-1. Immunoblotting was performed with a mouse monoclonal antibody directed
against mouse angiopoietin-1 (1:250; Abcam) and horseradish peroxidase–conjugated sheep
anti-mouse IgG enhanced chemiluminescence secondary antibody (1:20 000; GE Healthcare).
Chemiluminescent SuperSignal West Dura Extended Duration Substrate (Thermo Scientific)
was used, and images were captured with a ChemiDoc XRS+ system (Bio-Rad). Assays were
performed in triplicate.

5.1.2.9 In Vivo Inflammatory Analysis
To assess upregulation of inflammatory factors, hearts from all animals (control n=7,
SDF n=13, and ESA n=10) were explanted 2 weeks after LAD ligation, and myocardial tissue
biopsy samples were taken from the ischemic border zone. Samples were homogenized in TPer Tissue Extraction Reagent (Thermo-Fischer), normalized for total protein content via
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Quick Start Bradford Protein Assay (Bio-Rad), and tested for the presence of mouse tumor
necrosis factor- . Immunoblotting was performed with a rabbit polyclonal antibody directed
against mouse tumor necrosis factor-

(1:1000; Abcam) and horseradish peroxidase–

conjugated sheep anti-rabbit IgG enhanced chemiluminescence secondary antibody (1:3000;
GE Healthcare). Chemiluminescent SuperSignal West Dura Extended Duration Substrate
(Thermo Scientific) was used, and images were captured with a ChemiDoc XRS+ system
(Bio-Rad).
To further assess the inflammatory response after treatment, hearts from a subset of
animals (control n=4, SDF n=4, and ESA n=4) were explanted 2 weeks after LAD ligation, and
myocardial tissue biopsy samples were taken from the ischemic border zone. Samples were
homogenized in T-Per Tissue Extraction Reagent (Thermo-Fischer), normalized for total
protein content via Quick Start Bradford Protein Assay (Bio-Rad), and tested for the presence
of multiple inflammatory markers, including monocyte chemotactic protein-1, stem cell factor,
nuclear factor (NF)- B, phospho-NF- B, phospho-p38 mitogen-activated protein kinase,
phospho-Stat3, and phospho-I B- . Levels were quantified with the mouse inflammation
ELISA strip (Signosis) and the PathScan Inflammation Multi-Target Sandwich ELISA (Cell
Signaling Technology).

5.1.2.10 Echocardiographic Assessment of LV Geometry and Function
LV geometry and function were evaluated at 2 weeks (control n=7, SDF n=13, and
ESA n=10) after LAD ligation with a high-resolution (30 MHz) Vevo 770 transthoracic
echocardiography system (VisualSonic Inc). Four equally spaced short-axis acquisitions and 1
maximum long-axis cine-loop acquisition of the LV were recorded with the ultrahigh-frame-rate
EKVTM (ECG-based kilohertz visualization) acquisition mode. LV systolic function was
evaluated by a modified 4-plane Simpson method. LV cross-sectional areas were obtained by
tracing the diastolic and systolic endocardial borders in each of the 4 equally spaced LV short-
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axis slices. On the basis of these measurements and the Simpson length (d, s), the fractional
area change, ejection fraction, stroke volume, and cardiac output were computed with the
Vevo 770 Standard Measurement Package. Before and during the ultrasound scanning, the
mouse was lightly anesthetized with a mixture of 1% to 2% isoflurane gas and 100% oxygen
and was placed in the supine position on a heating platform. All analyses were performed by a
single investigator in a group-blinded fashion.

5.1.2.11 Statistical Analysis
Overall comparisons between the 3 groups were analyzed with a 1-way ANOVA. The
results are reported with F (a ratio of the variance between groups to the variance within
groups), 2 degrees of freedom, and the probability value. In addition, the unpaired Student t
test was used to compare individual groups. Values are expressed as mean±SEM. Statistical
significance was defined by P 0.05.

Figure 5.1. Crystallographic Structures of Stromal Cell–Derived Factor–1 (SDF) and Designed
Model Structure ESA. The different regions of the structure are colored as N–terminal (green), central
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region (yellow), and C –terminal (magenta). The central -sheet region (yellow) is replaced by a diproline
linker in ESA. The corresponding amino acid sequences of SDF–1 and ESA are also depicted, with the
different regions colored accordingly.

5.1.3 Results
5.1.3.1 Computational Protein Design, Modeling, and Synthesis
The crystallographic structure of SDF at 2.2 Å resolution was used to guide design
and modeling (Figure 5.1) [27]. The central -sheet region residues (amino acids 18 to 54)
were replaced with a 2-proline linker, which resulted in the 32-residue designed polypeptide
ESA. The coordinates of residues 14FESHPPL20 were allowed to relax on modeling with
MODELLER, whereas the coordinates of the remainder of the structure were constrained at
their crystallographic values. Fifty different possible structures were generated for peptides
with a 1-, 2-, or 3-proline linker. In general, the number of stable conformations increases
substantially as the number of linking amino acids is increased (Figure 5.2). The peptide with
the 2-proline linker (subsequently designated ESA) yielded energetic and conformational
advantages. The ESA peptide structure model with the lowest-scoring function was chosen for
further analysis. Importantly, the 2-proline residues were found to have energetically favorable
backbone dihedral angles (

and

) consistent with those observed for proline in natural

protein structures. The introduction of a 2-consecutive-proline linker does not produce steric
clashes within the modeled polypeptide structure. In addition, based on the calculated
structure, phenylalanine 14 (F14
(H17

ESA

), and leucine 20 (L20

ESA

ESA

) interacts with glutamic acid 15 (E15

ESA

), histidine 17

or L55 in SDF). These interactions are not present in the

crystallographic structure of SDF, and this group of residues may form a small clusterlike
structure that when coupled with the diproline spacer biases the peptide toward conformations
similar to those found in native SDF (Figure 5.3). Further structural analysis revealed that the
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model did not contain any steric clashes or unusual conformations of the backbone and the
amino acid side chains.

Figure 5.2. Top and Side View of Model Stromal Cell–Derived Factor–1

(SDF) Analog Peptides

Using 1-proline (a), 2-proline (b), and 3-proline (c) Residues to Link the N and C Terminus. The
images depict a composite of the 50 most energetically stable linker conformations of each peptide
sequence. The peptide with the 2-proline linker (b) adopts a more uniform tertiary profile than the others
and recovers the perpendicular orientation between the N– and C–termini found in native SDF.
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Figure 5.3. Space-Filling Representation of the ESA and SDF-1 Structures. The bulky side chain of
phenylalanine 14 (F14
extent leucine 20 (L20
and L55

SDF

ESA

ESA

) interacts with glutamic acid 15 (E15

ESA

), histidine 17 (H17

or residue 55 in native SDF-1 ). The interactions of F14

ESA

SDF

), and to some

, E15

SDF

, H17

SDF

,

were absent in the crystallographic structure of SDF–1 . These new interactions formed a

small clusterlike structure that when coupled with the diproline spacer (yellow in ESA) may help to
provide the necessary conformational stability and rigidity found in native SDF.

5.1.3.2 EPCs Cultured in Endothelial Specific Media Exhibit Enhanced Migration When
Exposed to an ESA Gradient
Using a Boyden chamber assay, 14-day cells showed increased migration when
placed in an ESA gradient compared with both recombinant SDF and saline (ESA 567±74
cells/high-power field [HPF] versus SDF 438±46 cells/HPF [P=0.037] versus control 156±45
cells/HPF [P=0.001]). Representative slides are shown in Figure 5.4. In addition, a 1-way
ANOVA was used to generate an overall comparison of the 3 study groups. EPC migration
differed significantly across the 3 groups, F(2,6)=41.27, P=0.0003. A dose-response curve
generated by comparing molar equivalents of ESA and SDF (Figure 5.5) demonstrated that
ESA significantly outperformed SDF at the high end of the concentration range but was
essentially equivalent to SDF for the low- and mid-range concentrations. Additionally, it was
revealed that the effectiveness of ESA and SDF was not linearly correlated to the dose
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concentration and that there was a significant decrease in EPC migration at the highest doses
for both.

Figure 5.4. Boyden Chamber Assays. Representative images of Boyden chamber assay filters
demonstrating green fluorescent protein–positive endothelial progenitor cell (EPC) migration when
exposed to a saline, stromal cell–derived factor–1
indicates high-power field.
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(SDF), and ESA gradient, respectively. HPF

Figure 5.5. EPC Dose Response Migration. Dose-response curve of endothelial progenitor cell (EPC)
migration comparing molar equivalent concentration gradients of ESA and stromal cell–derived factor–
1 (SDF). HPF indicates high-power field.

5.1.3.3 ESA Elicits Increased CXCR4 Receptor Activation In Vitro
Cells treated with ESA had greater levels of AKT phosphorylation than either
recombinant SDF (1.638±0.239 versus 1.258±0.187 OD, P=0.006) or control (1.638±0.239
versus 0.949±0.077 OD, P=0.0003). There was no significant difference in total AKT content
among the groups. In addition, a 1-way ANOVA was used to generate an overall comparison
of the 3 study groups. Levels of AKT phosphorylation differed significantly among the 3
groups, F(2,21)=38.56, P<1 10 7. The addition of the CXCR4 receptor antagonist AMD3100
to the culture media eliminated any difference in receptor activation between the groups (ESA
0.598±0.22 versus SDF 0.599±0.07 OD, P=0.49, and ESA 0.598±0.22 versus control
0.539±0.05 OD, P=0.27).
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5.1.3.4 EPCs Display Robust CXCR4 Expression When Treated With ESA
After exposure to ESA or SDF for 6 hours, isolated EPCs demonstrated diffuse
expression of the CXCR4 receptor (Figure 5.6).

Figure 5.6. CXCR4 Expression in EPCs. Isolated endothelial progenitor cells cultured and stimulated
with either stromal cell–derived factor–1

(A and B) or ESA (C and D) demonstrated robust and

universal expression of the chemokine receptor 4 (CXCR4 receptor; green). Nuclei are stained with
DAPI (blue).
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5.1.3.5 In Vivo Angiogenic Growth Factors Are Upregulated by ESA
At 2 weeks, immunoblotting revealed a significant quantitative increase in mouse angiopoietin1 expression in the ESA- and SDF-treated animals compared with the control group.
Quantitative analysis demonstrated intensities of 336±9 (ESA), 367±17 (SDF), and 234±7
(control) intensity units, respectively (P<0.001). A representative immunoblot is shown in
Figure 5.7.

Figure 5.7. In vivo Mouse Angiopoietin-1 Growth Factor. At 2 weeks, border-zone myocardial tissue
samples show increased levels of mouse angiopoietin-1 (Ang-1) in the ESA-treated and stromal cell–
derived factor–1

(SDF)-treated groups compared with the control group. GAPDH staining was

performed to demonstrate equivalent protein loading between lanes.

5.1.3.6 In Vivo Levels of Border-Zone Inflamatory Markers Are Not Statistically Different
Between Groups
At 2 weeks, immunoblotting revealed similar levels of tumor necrosis factor-

among

the ESA, SDF, and control groups. Quantitative analysis demonstrated intensities of
4784±274 (ESA), 4832±547 (SDF), and 4832±722 (control) arbitrary intensity units,
respectively. Statistical comparisons revealed no statistically significant difference (ESA
versus control, P=0.46; ESA versus SDF, P=0.4, SDF versus control, P=0.5). Additional
analysis demonstrated that after infarction and treatment, border-zone levels of the
inflammatory factors monocyte chemotactic protein-1, stem cell factor, NF- B, phospho-NFB, phospho-p38 mitogen-activated protein kinase, phospho-Stat3, and phospho-I B-
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were

either not significantly different or were significantly less in animals treated with ESA or SDF
than in saline control animals. These findings indicate that inflammation is not responsible for
the beneficial and proangiogenic effects of ESA.

5.1.3.7 Echocardiographic Assessment Demonstrates Enhanced LV Function After ESA
Treatment
Echocardiographic assessment of cardiac function demonstrated significant benefits
in the ESA group compared with the control group. At 2 weeks, ESA animals had a
significantly improved ejection fraction (57±2.9% versus 42±1.6%, P=0.002), cardiac output
(30±1.8 versus 23±1.3 mL/min, P=0.01), stroke volume (61±3.6 versus 48±2.9

L, P=0.02),

and fractional area change (52±3.6% versus 29±4.9%, P=0.001) compared with controls. The
ESA-treated mice also had a significantly increased fractional area change compared with
SDF–treated mice (52±3.6% versus 42±3.2%, P=0.04) and a strong trend toward
improvement in all other ventricular function parameters assessed (Table 5.1). A 1-way
ANOVA was used to generate an overall comparison of the 3 study groups for each cardiac
functional parameter. Values differed significantly across the 3 groups for ejection fraction
(F(2,27)=5.71, P=0.009), cardiac output (F(2,27)=3.98, P=0.03), stroke volume (F(2,27)=3.83,
P=0.03), and fractional area change (F(2,27)=7.91, P=0.002).

Table 5.1. Left Ventricular Function Assessed by Transthoracic Echocardiography. At 2 weeks,
ESA-treated animals demonstrated improved left ventricular function by transthoracic echocardiography.
SDF indicates stromal cell–derived factor–1 .
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5.1.4 Discussion
Angiogenic cytokine therapy for ischemic heart disease has proven to have great
potential in numerous preclinical and clinical trials. The ability to replenish myocardial
microvasculature could prove lifesaving to the millions of patients with myocardial ischemia.
SDF, in particular, is among the most potent and specific angiogenic cytokines; its sole target,
+

the CXCR4 cell surface antigen, is expressed in significant levels on CD34 EPCs, and
expression of this receptor is related to efficient SDF-induced transendothelial migration [28].
SDF repeatedly has been shown to play a critical role in the rescue of myocardial function and
stem cell recruitment to the heart after myocardial infarction [19,20,29-33]. However,
significant barriers remain between the diverse experimental successes of SDF angiogenic
cytokine therapy and its widespread clinical translation. SDF is a large, complex 10-kDa
protein that is expensive to manufacture and is readily inactivated by proteases that are
upregulated at the time of myocardial infarction [34,35]. It is our belief that smaller, synthetic
analogs of SDF can provide translational advantages over the native protein, including
enhanced stability and function, ease of synthesis, lower cost, and potential modulated
delivery via engineered biomaterials. In the present study, we used advanced computational
protein design techniques to create a more efficient and translatable molecule (ESA) evolved
from the native SDF protein.
The ESA peptide was engineered to link the native N–terminus (responsible for
receptor activation and binding) and the C–terminus (responsible for extracellular stabilization)
with a diproline amino acid spacer. Although ESA may not have a well-defined tertiary
structure, the linker is designed to bias the polypeptide toward structures that present the N–
and C–termini in a manner similar to that present in the native SDF protein. On the basis of
the modeled structure, F14

ESA

is in proximity to E15

ESA

, H17

ESA

, and L20

ESA

, forming a small

cluster of side chains within ESA (Figure 5.3). These interactions, coupled with the diproline
linker, may provide a conformational bias sufficient to recover the activity associated with
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SDF. The end product, ESA, is a novel polypeptide that contains less than half the number of
amino acid residues, is less than half the molecular weight, and has enhanced physiological
performance compared with recombinant SDF.
The SDF chemotactic homing mechanism is central to its ability to increase periinfarct microvasculature and prevent mechanically inefficient ventricular contraction and
eventual heart failure. Using a Boyden chamber assay to directly quantify the magnitude of
cellular migration, we were able to demonstrate significantly enhanced migration of endothelial
progenitor stem cells when placed in an ESA gradient compared with native SDF peptide. This
result shows that for the same mass concentration, ESA not only retains this important
function, despite its reengineered conformation, but surpasses the native protein. Compared
with SDF, the relatively small size of ESA may enhance its diffusion potential and the speed at
which the chemotactic signal is deployed. However, rapid diffusion is likely not the only factor
that leads to significantly greater EPC migration. It has been shown that AKT activation is
required for SDF-induced cellular migration [36]. To evaluate the EPC response to ESA, we
incubated EPCs with culture media that contained ESA, recombinant SDF, or media only
(control) and quantified both phosphorylated and total AKT levels by ELISA. In concordance
with the results of the EPC migration assay, we were able to demonstrate significantly
increased CXCR4 receptor activation and phosphorylated AKT levels in response to ESA
compared with SDF. The addition of the CXCR4 antagonist AMD3100 eliminated this
difference in receptor activation between ESA, SDF, and control, which confirms its receptor
specificity. It is difficult to speculate which specific receptor-peptide interactions are
responsible for the enhanced activation of CXCR4 by ESA, and future computational studies
will be used to understand the surprisingly efficient activity of this novel polypeptide on a
molecular level.
It is our belief that ESA, in a similar fashion to SDF, increases border-zone
microvasculature, which in turn reverses cellular ischemia, preserves cardiomyocyte viability,
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and increases the mechanical efficiency of peri-infarct myocardium. In support of that
hypothesis, we have shown that border-zone myocardium treated with ESA has significantly
upregulated levels of angiopoietin-1, indicative of an ongoing angiogenic process as late as 2
weeks after infarction and treatment. One could argue that the mechanism responsible for the
upregulated angiogenic activity is an exaggerated inflammatory response that results from the
injection of ESA or even SDF. However, analysis of border-zone tumor necrosis factor- ,
monocyte chemotactic protein-1, stem cell factor, NF- B, phospho-NF- B, phospho-p38
mitogen-activated protein kinase, phospho-Stat3, and phospho-I B-

revealed that levels of

inflammatory markers were not increased in experimental animals compared with controls,
which indicates that the beneficial angiogenic and functional effects were not the result of
differing levels of inflammation.
An increase in microvascular perfusion should result in decreased ventricular
remodeling, improved regional ventricular function, and slower progression toward heart
failure. Left ventricular geometry and function were evaluated at 2 weeks after LAD ligation
with a high-resolution (30 MHz) transthoracic echocardiography system. The improved
functionality of ESA in vitro was, once again, borne out in vivo. Animals treated with
intramyocardial injections of the ESA peptide had better ejection fractions, cardiac output,
stroke volume, and fractional area contraction than either the SDF or control group.

5.1.5 Conclusion
In conclusion, we have been able to engineer a novel, low-molecular-weight
polypeptide with the enhanced physiological ability to induce EPC migration and EPC receptor
activation and improve ventricular performance compared with native SDF. This peptide offers
a more clinically translatable neovasculogenic therapy that could conceivably be deployed at
any point in the time course of ischemic heart disease to address critical deficits in
microvascular perfusion.
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5.2 Molecular Dynamics Simulations of Stromal Cell–Derived Factor–1
Peptide Analogs with Enhanced Chemotactic Activity

and Simplified

1

5.2.1 Introduction
Chemokines are a family of small (8 10 kDa) secreted proteins that posses
chemoattractant properties [37,38]. This type of cytokines directs cell migration and
proinflamatory immune responses by specific activation of their receptors expressed on the
cell surface. The chemokine receptors are part of the large family of seven transmembrane G
protein coupled receptors (GPCRs) [39]. In addition, chemokines play an important role in
promoting the creation and regulation of new blood vessels (angiogenesis and angiostasis)
[37,40]. Chemokines are divided in four families based on the arrangement and number of
cysteine residues in the N terminus, i.e., CXC, CC, CX3C, and C [37,38].
Stromal cell derived factor 1 (SDF 1 or CXCL12) is a member of the CXC
chemokine family and is responsible for the migration of a variety of cells, including monocytes
and lymphocytes [38]. It is constitutively secreted from the bone marrow stromal cells and it
plays a central role in the hematopoietic stem cell trafficking [41,42]. SDF 1 is the ligand of
the CXC chemokine receptor 4 (CXCR4). The SDF-1/CXCR4 signal axis has been shown to
play essential roles in: hemotopoiesis, stem/progenitor cell trafficking, stem-cell homing,
cancer progression-growth, metastasis, neovascularization and angiogenic processes [11,4346]. Furthermore, mice lacking the SDF–1 or the CXCR4 gene die in utero with a number of
developmental abnormalities indicating the critical role of SDF–1 and CXCR4 in embryonic
development [47-49].
Three variants of SDF 1 are produced by alternative splicing of the same gene, i.e.,
SDF–1 , SDF–1 , and SDF–1 [50]. SDF-1

is the most abundant form and is composed of

68 residues. SDF–1 contains four additional residues in the C terminus while the SDF–1
variant contains a more extensive C terminus with a different amino acid composition. SDF–
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1

assumes the conventional chemokine topology as shown by its NMR [22,51] and crystal

structures [27,52,53]. It is composed by an unstructured N–terminus (K1 to R8), a long flexible
loop that contains the CXC conserved motif (denominated N–loop), a three-stranded antiparallel -sheet, and an

-helix. Interestingly, two disulfide bonds formed by residues at the

N–loop and the -sheet region, restrict the conformations of SDF–1 .
The interaction of SDF–1

with the CXCR4 receptor has been widely studied

[38,45,46] and the current binding model suggests a two-step/two-site mechanism [22,54].
First is the interaction between SDF–1

(through its -sheet, 50–s loop and N–loop) and the

CXCR4 extracellular region. After SDF–1

is effectively anchored on the extracellular region

of CXCR4, its highly dynamic N terminus efficiently searches and binds a cavity within the
transmembrane helices that triggers the conformational changes needed for signal
transduction [54], pressumably by the fly-casting mechanism [55].
Based on the relevance of the SDF–1 /CXCR4 system, its potential role as a
therapeutic target for treatment of different disorders (e.g., cancer progression-growth,
metastasis, inflammatory and infectious diseases, etc) has been extensively explored [40,56].
Of particular relevance are its roles in the growth of new blood vessels from existing ones
(angiogenesis) and the de novo formation of vessels from endothelial progenitor cells
(vasculogenesis). These provide a promising treatment for inadequate blood supply to the
heart (ischemic heart disease), which has been predicted to be the leading cause of death
worldwide in the near future [11,46].
For instance, externally administered SDF–1

to ischemic myocardium has been

demostrated to produce beneficial effects such as increase circulating endothelial progenitor
cells (EPC), increment in the de novo formation of vessels (vasculogenesis), increase in
myocardial function, and preservation of ventricular geometry, just to mention some [19,20].
Despite its potential as a therapeutic agent for treatment of cardiovascular disorders,
SDF–1

presents features that preclude its translation to general clinical therapy.
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Recombinant SDF–1

suffers proteolysis by different proteases [21,35], has a complex

tertiary structure that involved two disulfide bonds [22], and is relatively large and expensive.
Hiesinger et al. recently proposed a promising alternative based on computationally
designed SDF–1

analogs that used a proline residue linker to connect the N–terminus and

part of the N–loop (K1 to H17) with the -helix at the C–terminus (L55 to N67) [57]. The study
showed that proline analogs performed similarly and in some cases, outperform recombinant
SDF–1 in cell-based assays. Moreover, one of the analogs outperformed recombinant SDF–
1

in a murine model of ischemic heart failure [57]. In this study, a detailed analysis of the

conformations of SDF–1

and some simplified analogs was carried out. Molecular dynamics

(MD) simulations were performed to obtain insights of the conformations explore by SDF–1
and the different analogs in water environment and under physiological conditions of
temperature and pressure. MD simulations suggest that the analogs explore similar
conformations as native SDF–1 , especially the two-proline (2P) analog. MD simulation
results are in close agreement with experimental results using a migration assay and a
receptor activation assay [57]. Hypotheses about the reasons of enhanced activity of the twoproline analog relative to native SDF–1

in both, cell-based assays and in the murine model

of heart failure are exposed and discussed in regard to experimental findings.
5.2.2 Methods
5.2.2.1 Initial Structures
The crystal structure of SDF–1

at 2.2 Å resolution was used [27]. The complete

structure was reconstructed using the CHARMM topology files. The modeling of the simplified
SDF–1

analogs is described previously [57]. Briefly, the crystal structure of SDF–1

was

used to guide the design. The segment of the protein composed by the -sheet region was
replaced by linkers made of one (1P), two (2P), and three (3P) proline residues using
MODELLER [25]. An additional linker composed of two glycine residues was also considered
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(2G). Finally, for the analog with a linker of three prolines, two mutations in the

-helix were

suggested (I58E and L62K) to increase the helix stability (3P_I24E_L28K). The initial
structures utilized for the molecular dynamics simulations are shown in figure 5.8.

5.2.2.2 Molecular Dynamics Simulations
All-atom molecular dynamic simulations were performed on the SDF–1 structure and
the simplified analogs. The simulations were carried out using NAMD2 [58] and the
CHARMM22 force field [59]. The best structure from the comparative modeling was minimized
after addition of hydrogen atoms for 5000 steps using NAMD2 [58]. Water molecules (TIP3P)
+

–

[60] and sodium (Na ) and chlorine (Cl ) ions [59] were included and minimized with the
protein atoms fixed followed by a short MD simulation (5.0 ps with 1.0 fs time step). The
protein was then minimized to adjust to the new environment for 10000 steps followed by
another 10000 steps minimization of the entire system. Finally, the MD simulation on the
entire system was carried out in the NPT ensemble. Langevin dynamics and the hybrid NoséHoover Langevin piston were used to maintain constant temperature (310 K) and constant
pressure (1atm), respectively [61]. Electrostatic interactions were evaluated using the Particle
Mesh Ewald technique with a grid spacing less than 1.0 Å for each dimension and a fourthorder interpolation [62]. Periodic boundary conditions were used with a periodic cell of 55 Å
52 Å

69 Å. Bond lenghts involving hydrogen atoms were constrained to their equilibrium

values [59] by using the SHAKE algorithm [63]. A time step of 2.0 fs was used during the
simulations.
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Figure 5.8. Initial Structures (With Sequences) of SDF–1
Molecular Dynamics Simulations. The regions of SDF–1

and the Simplified Analogs Used for the
and analogs are colored as follows: N–

terminus in green, -region/Linker in yellow, and C–terminus (including the -helix) in magenta. The rootmean square deviation (rmsd) plots relative to the initial structure for the production phase (100 ns) are
also shown. The C atoms involved in the calculation of the rmsd are depicted as blue spheres. To avoid
noise from the highly dynamic N–terminus, the first eight residues were excluded in the rmsd
calculations.

5.2.2.3 Overlap Distribution Calculation
The overlap distribution ( ) calculation was done using the following equation:

( 1, 2 ) =

1
N

W
1i
i=1

2
1i

where N is the total number of points,

2i

(5-1)

2
2i

1i

and

2i

are the values for the first and the second

histograms, respectively. The sum is over the different “bins” in the histrograms. W is the
number of bins. The denominator is the normalization factor. A value of 0 means there is not
overlap for the two distributions whereas a value of 1 means a maximum ovelap (equal
distributions).

5.2.3 Results
5.2.3.1 Structural Parameters and General Dynamics of the Systems
The equilibriation of the different systems was monitored by changes in structural
parameters such as the root-mean square deviation (rmsd) relative to the initial structure. The
production phase for each of the systems was 100 ns. In the case of SDF–1 , the rmsd of the
C atoms was used to monitor the dynamics of the protein. It was evident from the results that
the highly dynamic N–terminus was introducing noise in the analysis (figure 5.9a), so a subset
of the 68 C atoms of SDF–1 was chosen (from C9 to A65). The rmsd of the C atoms from
C9 to A65 is shown in figure 5.8 and 5.9a. For consistency, the equivalent residues in the
SDF-1 analogs were used in the calculations of rmsd.
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Figure 5.9. Root-mean Square Deviations (rmsd) and Root-mean Square Fluctuations (rmsf) of
SDF–1 , and Distributions and PSI and PHI Backbone Angles of the 2P and 2G Analogs. (a) Rmsd
for the entire trajectory (~110 ns) for SDF–1

1-67

and SDF–1

9-65.

Inclusion of the highly dynamics N–

terminus segment (K1-R8) produces large fluctuations in the rmsd that are not present when this
segment is excluded from the calculations. The production phase is highlighted in red. (b) SDF–1 rootmean square fluctuations for the C atoms for the MD trajectory (100 ns). The thickness and color of the
rederings are related with the rmsf value. (c-f) Distributions of the
residues in the 2P and 2G analogs. (g-n) Distributions of

and

and

backbone angles for all the

angles for the residues that formed the

linker in 2P and 2G analogs.

Additionally, the root-mean square fluctuations (rmsf) were calculated for the entire
production phase and the results for SDF-1

are presented in figure 5.9b. From the rmsf

results, it is evident the most dynamics part of the structure reside in the first segment of the
N–terminus, K1 to R8. The disulfide bonds between C9-C34 and C11-C50, seem to
significantly restrain the movement of the rest of the N–terminus (see figure 5.8).
In the case of the different analogs the conformations from the linker residues are in
agreement with values seeing in natural proteins. As expected the proline residues forming
the linker present a very narrow distribution of the phi ( ) and psi ( ) angles through the entire
trajectory while the glycine residues explore a relatively wide distribution, see Figure 5.9c-n.

5.2.3.2 Simplified Parameters to Monitor the Dynamics of SDF-1

and its Analogs

Instead of using techniques to reduce the dimentionality of the variables involved in
the conformations explored by SDF–1

and the analogs, e.g., principal component analysis,

we decided to identify simple parameters with straightforward physical interpretation. For this
reason three parameters were defined and monitored: i) the distance between the C
of residue C9 and L55 (located before the beginning of the

atoms

-helix in the C–terminus), ii) the

distance between the C atoms of residues C9 and A65 (last residue of the -helix in the C–
terminus), and iii) the angle formed by the C atoms of C9-L55 and A65, see figure 5.10.
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To explore the similarities in the conformations sampled by SDF–1 and its simplified
analogs, the distributions of the values adopted by the systems were obtained. The different
histograms were compared and the overlaps calculated using equation 5-1. The results are
presented in figure 5.10. The values of the overlap range from 0 (no distribution ovelap) and 1
(complete distribution overlap). Based on the distributions of these three parameters, it seems
that the analogs sample similar conformations than SDF–1 . In the case of distance1 (C9L55), the 3P_I24E_L82K and 2G analog sample similar values than SDF-1 , but for the rest,
there is still significant overlap in all the analogs but 1P. For distance2 (C9-A65), the results
shown a better overlap for 1P and 2P with significant values for all the rest analogs but
3P_I24E_L82K. In the case of angle1 (C9-L55-A65), all the distributions seem to overlap
significantly, with the oustanding case of the 1P and 2P analogs. It is our belief that the
position of the N–terminus relative to the rest of the structure could be important in the
interactions of SDF–1 with its native target receptors.
The findings from this analysis indicate that in general and based on the three
parameters defined previously, all the simplified analogs of SDF–1

explore to a certain

degree, conformations similar to the native SDF–1 . A product of the values for the overlap of
the three parameters suggests that the rank of similarity between SDF-1

and the simplified

analogs is 2P (0.083) > 2G (0.059) > 1P (0.015) > 3P (0.012) > 3P_I24E_L82K (0.003). The
results based on this analysis are in agreement with experimental findings that show that the
2P analog bahaves similarly to native SDF–1 in a migration assay and a receptor activation
assay [57].
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Figure 5.10. Parameter Defined to Monitor the Dynamics of SDF–1

and the Simplified Analogs.

Three parameters, two distances and one angle are defined in the SDF–1 structure (top panels). The
distributions of the values sampled along the MD simulations of the simplified analogs are compared with
the distribution sampled by SDF–1 . The similarity (overlap) of the distributions is expressed by the
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number at the top right corner of the histograms, were 0 represents no overlap and 1 represents a
complete overlap.

5.2.3.3 Comparison of Superimposed Structures
A structure from the entire 100 ns MD trajectory was extracted every 2.0 ns and a
comparison of the 50 resulting structures is presented in figure 5.11 for SDF–1
simplified analogs. From the MD trajectories different features for SDF–1

and the

and each of the

simplified analogs can be deduced.
SDF–1 : Based on the rmsd and the MD trajectories, the different conformations explored by
SDF–1 at this time scale are similar ( rmsd = 2.79 Å) than the initial structure (based on the
X-ray crystal structure, 1A15.pdb; chain A [27]). As expected, the N–terminus is highly
dynamic and explores a significant space volume with a radius of gyration for the nitrogen
atom of the first residue (K1) of 14.79 Å. Starting at residue C9, the structure samples less
diverse conformations that resemble the initial structure. As suggested previously, the
presence of the two disulfide bonds (C9-C34 and C11-C50) seems to aid in maintaining the
tertiary structure of SDF–1 . The secondary structure is well maintained during the simulation
as indicated in figure 5.11 (Top left panel).
1P analog: Interestingly, the MD simulations indicate a disruption of the

-helical structure in

the analog with one-proline linker. The N–terminus is still very flexible with radius of gyration
for the nitrogen atom of the first residue (K1) of 13.91 Å. The lack of the disulfide bonds seems
to produce a highly flexible peptide, see figure 5.11, top right panel.
2P analog: MD simulations indicate that even though there are no disulfide bonds present in
the peptide, the general topology of 2P resembles the tertiary structure of native SDF–1
(figure 5.11, middle left panel). Contrary to the 1P analog, the secondary structure of the

-

helix is retained. The N–terminus is highly flexible and explores an even larger space volume
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than SDF–1

as indicated by the radius of gyration of the nitrogen atom of the first residue,

17.13 Å.
2G analog: The flexible residues in the linker of this peptide seem to allow the proximity of part
of the N–terminus with the

-helix at the C–terminus (resembling an inverted “U” from the

poses in figure 5.11, middle right panel). The structure of the

-helix is retained and similarly

to SDF–1 , 1P and 2P, the N-terminus explores a significant space volume with a radius of
gyration for the nitrogen atom of the first residue of 14.96 Å.
3P analog: The MD simulations show a similarity in the general conformation explored by 2G
and 3P. In a similar fashion, part of the N-terminus of 3P, samples conformations that are in
the vicinity of the -helix at the C-terminus, forming an inverted “U” topology, see figure 5.11,
bottom left panel. The secondary structure of the

-helix is conserved and the N–terminus

also explores a significant space volume with a radius of gyration of 13.10 Å for the nitrogen
atom in the first residue.
3P_I24E_L28K analog: Finally, a similar behavior than 2G and 3P is displayed regarding the
proximity of the N– and C–terminus (inverted “U” topology, see figure 5.11 bottom right panel).
Although the structure of the

-helix is conserved, the space volume explored by the N–

terminus is dramatically reduced as suggested by the radius of gyration of the nitrogen atom
of the first residue, 3.91 Å.
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Figure 5.11. Superimposed Structures for SDF–1

and the Simplified Analogs Taken Every 2.0 ns

for the Entire Production Phase (100 ns). For clarity and to indicate the positions of the N– and C–
terminus, the first and last residues in the structures are colored in pale blue and red, respectively. In the
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analogs, the residues forming the linker are colored in yellow. Finally, the positions that determined the
parameters defined to monitor the dynamics of the structures are colored in blue.

5.2.3.4 Space Volume Sampled by the N–terminus, Radius of Gyration of the Center of
Mass of Segment K1-R8
It has been shown that the N–terminus is responsible for the interaction and activation
of SDF–1

with its native receptors [22]. To have further insights into the similarities of the

conformations explored by the highly dynamic N–terminus of SDF–1

and the analogs, we

simplified the degrees of freedom to only the center of mass of the segment K1-R8 and then
compared the regions explored along the 100 ns of the MD trajectories.
Sampled structures along the MD simulations were aligned to the initial structure in
each case. The alignment was based on the C

atoms of the

-helix, e.g., K56 to A65 (or

equivalent positions in analogs). Then, the center of mass of the C atoms of the segment K1R8 was calculated (see small spheres in Figure 5.12). The cloud of points (and its center)
generated for SDF-1

and the simplified analogs is shown in figure 5.12, in blue and red,

respectively. In comparing the overlap, the initial structure of SDF–1

and the analogs were

used and the transformation matrix needed to obtain the best-fit alignment between the
analogs and SDF–1 was calculated. The atoms involved in the calculation were C9-H17 and
K56-A65 (SDF-1 ) and the equivalent residues in the analogs (the subset is composed of N–
terminal residues involved in the rmsd calculation and the residues in the -helix, i.e., residues
that are common in all the structures). The same transformation matrix was applied to the
points from the analogs and the overlap was calculated using equation 5-1. The values
obtained for the overlap were: 1P (0.000), 2P (0.011), 2G (0.007), 3P (0.001), and
3P_I24E_L28K (0.000). Although small, the overlap for the center of mass of the N–terminus
suggests that the 2P analogs displays more similarities (with SDF–1 ) in the conformations
explored than that rest of the analogs, see figure 5.12. Furthermore, the results from the
overlap of the spatial region sampled by the N–terminus suggest the SDF–1 similarity rank:
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2P > 2G > 3P > 1P = 3P_I24E_L28K. Based on the overlapping values it is not possible to
discriminate between 1P and 3P_I24E_L82K, but based on the visual considerations, we
could speculate that 3P_I24E_L82K would diverge more from SDF–1

in the conformation

explored by both structures. The final similarity rank from this section is 2P > 2G > 3P > 1P >
3P_I24E_L28K. This is slightly different (order of 1P and 3P analogs) than the rank proposed
previously (using three parameters), 2P > 2G > 1P > 3P > 3P_I24E_L82K.
In addition to the overlaps, figure 5.12 also contains information about the relative
position of the center of the cloud of points for SDF–1 and the simplified analogs. In the case
of SDF–1 , the center is located in front of the helical positions (see yellow spheres in figure
5.12) that face the -region. The central region and the disulfide bonds seem to preclude the
proximity of the N–terminus to the -helix.
In the case of 1P, the center is located behind the “reference positions” (yellow
spheres), which in the case of SDF–1 , face the -region. Similar to SDF–1 , the center in
the case of 2P is located in front of the reference positions that originally face the -region.
The absence of the

-region and the disulfide bonds allows the N–terminus to explore

conformations closer to the -helix. Similar to the center of 2P, the center of the 2G analog is
located in front of the reference positions but perhaps due to the large flexibility of the residues
composing the linker, the center is closer to the -helix. The center of 3P is located in a very
similar position as 2G. Finally, in the case of 3P_I24E_L28K, the center is very close to the helix located at the C–terminus.
From this section the results indicate the features of the different regions of space that
are sampled by the N–terminus of SDF–1

and the simplified analogs. Again, the 2P analog

seems to mimic better the conformations of native SDF–1 . In contrast, the conformations of
the N–terminus of the 3P_I24E_L28K analog are restricted to a relative small volume and also
they diverge more from those explored by SDF–1 .
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Figure 5.12. Space Sampled by the Center of Mass of the Highly Dynamic N–terminus (K1-R8)
Along the MD Simulations. The left panels present comparisons of the space volume explored by the
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center of mass of the N-terminus (K1-R8; small spheres, represent the positions of C for K1 and R8) of
both, SDF–1

(blue) and the simplified analogs (red). The center of the each of the cloud of points is

represented as blue (SDF–1 ) and red (analogs) spheres, respectively. As reference, the C atoms for
the equivalent positions I58E and L62K, are rendered as yellow spheres in the analogs structures. These
helical positions are facing the -region in SDF–1 . The overlap for each of the analogs was: 1P (0.000),
2P (0.011), 2G (0.007), 3P (0.001), and 3P_I24E_L28K (0.000). Middle and right panels show two
different views of the center of the points explored by the center of mass of the segment K1-R8 in the
MD simulations for SDF–1 (blue) and analogs (red).

5.2.3.5 Comparison of Current Crystal and NMR Structures of SDF–1

with the Average

Structure from MD simulations
It is worthwhile to compare the average structure of SDF–1 from the MD simulations
with the currently available crystal and NMR structures. The initial geometry used in the
current study is based on the chain A of the crystal structure, 1A15.pdb [27]. For the
production phase (100 ns), the average positions of the backbone atoms were calculated and
the structure was compared with the experimentally determined structures from NMR and Xray crystallographic techniques. The structures used were 1SDF.pdb (NMR) [22], 1A15.pdb
(X-ray, 2.20 Å) [27], 1QG7.pdb (X-ray, 2.00 Å) [52], 1VMC.pdb (NMR) [51], and 2J7Z.pdb (Xray, 1.95 Å) [53]. The results are present in figure 5.13.
The rmsd values indicate that the average structure is closer to the NMR structure
1VMC for the entire segment C9-A65. Interestingly, for the same alignment and as indicated
by the rsmd57-65 values, the position of the

-helix relative to the rest of the structure

resembles more the position in the first NMR structure (see Figure 5.13b). Both NMR
structures were characterized as monomers.
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Figure 5.13. Comparison of the Average Backbone Structures from the MD Simulations With
Current Structures of SDF–1 . (a) Superimposed SDF-1

structures: 1SDF.pdb (magenta) [22],

1A15.pdb (yellow) [27], 1QG7.pdb (green) [52], 1VMC.pdb (purple) [51], and 2J7Z.pdb (orange) [53]. (b)
Comparison of average structure from MD simulations (gray), and the two NMR structures, 1SDF.pdb
(magenta) and 1VMC (purple). (c) Root mean-square deviation of the experimentally determined
structure and the average structure from MD simulations. The structural alignment was done using the
backbone atoms from residues C9 to A65. Although the rmsd with 1VMC is the lowest considering the
segment C9-A65, the positions of the

-helix relative to the rest of the structure resembles more the

1SDF.pdb structure (rmsd of residues W57-A65).

5.2.4 Discussion
Stromal cell–derived factor–1

(SDF–1

or CXCL12 ) is a powerful chemoattractant

important in orchestrating migratory responses involved in inflamatory reactions. This small
67-residue protein presents a typical chemokine tertiary structure composed of N–terminus,
N–loop, a

-sheet region composed of three

strands, and an

-helix at the C–terminus.

There are two difulfide bonds that help to maintain the native conformation of SDF–1 .
Despite the fact that the disulfide bonds restrain the conformations of part of the structure, the
N–terminal segment composed of residues K1 to R8, has been demostrated to be highly
flexible and unstructured [22]. Furthermore, it has been demostrated by mutagenesis studies
that the N–terminus is crucial for the binding and for signal transduction [22]. Due to the
relevance in different physiological processes, the interactions between SDF–1

and the

CXCR4 receptor has been extensively studied. The current model of interaction suggests a
two-step/two-site mechanism [22,54]. New evidence suggests that the interactions between
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the two sites are independent of each other, that is, the first interaction of SDF–1 with the N–
terminus of the CXCR4 is independent of the second interaction between the N–terminus of
SDF–1 and the transmembrane region of CXCR4 [54]. Additionally, it was been demostrated
that quaternary structure of SDF–1

is sensitive to a different factors such as pH, specific

anions, heparin, and the presence of CXCR4 [64].
The SDF–1 /CXCR4 system has be investigated as a therapeutic target for the
treatment of different disorders [40,56]. Particularly relevant is its possible role in the treatment
of cardiovascular diseases [12,46].
A recent study has shown the possibility to use simplified analogs as an alternative
neovasculogenic therapy [57]. Here we used molecular dynamics simulations to get insights
into the conformations sampled by native SDF–1

and simplified analogs. Different analysis

proposed a possible molecular explanation for the beneficial properties of the simplified
analogs in mimicking the properties of native SDF–1 .

5.2.4.1 Conformations of SDF–1

and the Simplified Analogs

The findings from MD simulations using two different approaches to compare the
conformations sample by SDF–1

and the simplified analogs, suggest that the two-proline

analog 2P outperforms the other simplified analogs in mimicking such conformations. This
results are in agreement with the experimental finding using a EPC migration and a CXCR4
activation assays [57].

5.2.4.2 Monomer–Dimer Equilibrium and Possible Reasons of the Enhanced Activity of
the 2P Analog Relative to Native SDF–1
To study the role of posttranslational modifications of the N–terminal domain of
CXCR4 and its implication in the recognition of SDF–1 , an engineered covalently locked
dimer of SDF–1

(denominated SDF12) was created to simplified the determination of the
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interactions between SDF–1

and a peptide derived from the N–terminal domain of CXCR4

[65]. The structure of SDF12, determined by NMR, was in close agreement with the wild-type
dimer determined by X-ray crystallography [52]. Surprisingly, the covalently locked dimer was
able to induce intracellular Ca

2+

mobilization in human acute monocytic leukemia (TPH-1)

cells but had no chemotactic activity. Moreover, SDF12 inhibits migration of THP-1 cells in
response to wild-type SDF–1 and therefore was suggested to act as a potent partial agonist.
Also, the role of the shift in oligomeric state was tested using a SDF–1
remains monomeric at higher concentrations. SDF–1

mutant (H25R) that

displays a biphasic dose-dependent

chemotactic response that decreases at higher concentrations. Interestingly, the SDF–1
mutant (H25R) was shown to maintain chemotactic responses at higher concentrations than
native SDF–1 [65]. The final conclusion was that at low concentrations the monomeric SDF–
1

is largely dominant and it is responsible for stimulating chemotaxis, whereas at higher

concentrations and perhaps promoted by species such as heparin or CXCR4, the dimeric form
starts to be dominant and it is resposible for interference with chemotactic signaling [65].
Additionally, Hiesinger et al. performed similar migration studies in endothelial
progenitor cells and found similar results, where a biphasic dose-dependent chemotactic
response was observed [57]. In this case, the 2P analog (denominated ESA) displayed
chemotactic activity at higher concentrations than native SDF–1 . Following similar rationale
than in the SDF–1 mutant (H25R), we speculate that the outperformance of the simplified 2P
analog is related with its tendency to remain monomeric at high concentrations. As shown in
the X-ray structure of the SDF-1
(2K01.pdb), the

dimer (1QG7.pdb) [52] and the engineered SDF12

-sheet region and particularly the first

-strand (23VKHLKIL29), is

responsible for a large portion of the protein-protein interactions that stabilize the dimer [64]. In
the simplified peptide analogs, the -sheet region was completely removed and with it, some
of the interactions that stabilize the dimer formation. To explain the benefits obtained for the
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2P simplified analog of SDF–1 , we hypothesize that by removing the

-sheet region, the

monomer-dimer equilibrium was shifted to the monomeric form and therefore, the oligomeric
state responsible for inducing chemotaxis is present at higher concentrations than in the case
of native SDF–1 .

5.2.5 Conclusions
Molecular dynamics simulations have been used to elucidate atomistic details of
SDF–1 and simplified analogs. The results show that in aqueous at physiological conditions
of temperature and pressure, the two-proline analog explores similar conformations as native
SDF–1

under similar simulation conditions. The agreement between experimental and

computational findings suggest that MD simulations could be used not only to provide insights
into the molecular mechanisms of this type of systems but also to predict protein behaviours in
different experimental assays.
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6

Multiple Hindered Rotators in a Gyroscope-Inspired

Tribenzylamine Hemicryptophane1, 2

6.1 Introduction
Synthetic chemical systems provide means to explore complex phenomena in
biological machines [1-8] and also to create novel molecular mechanical components [9].
Designs based on macroscopic devices include brakes, gears, propellers, rachets, turnstiles,
rotors, scissors, and most recently gyroscopes [3,10-14]. These molecular systems have been
extensively studied in solution, in solid phases, on surfaces and in polymers [15]. One
challenge in designing these systems is the required restriction of some molecular degrees of
freedom, while allowing specific motions of targeted molecular components [9]. Although
synthesis of such molecules can also be challenging, criteria for the construction of molecular
gyroscopes have been identified and generally applied: rotary elements (rotators) are attached
to a static framework (stator); steric contacts, internal rotation barriers, and interaction with
solvent should be minimized to allow low-friction, low-barrier rotary motion; rotating groups are
isolated and/or well-separated from each other. To expand upon these criteria, we designed a
gyroscope-inspired framework with cyclotriveratrylene (CTV) and trismethylamine as the twocomponent stator, bridged by three p-phenylene rotators (Figure 6.1). Previously, two
opposing CTV units have been linked to generate cryptophanes with suitable for host-guest
chemistry, as well as biosensing and chiroptical properties [16-31]. CTV has also been
employed in supramolecular assemblies, gels and organic microporous polymers [32].

1

This project was a collaboration with the group of Professor Ivan J. Dmochowski at the
Department of Chemistry, University of Pennsylvania, Philadelphia, PA 19104.
†
†
2
Adapted from Najat S. Khan , Jose Manuel Perez-Aguilar , Tara Kaufmann, P. Aru Hill,
Olena Taratula, One-Sun Lee, Patrick J. Carroll, Jeffery G. Saven, Ivan J. Dmochowski J. Org.
†
Chem. 2011, 76, 1418-1424. Copyright 2011 American Chemical Society. N.S.K. and J.M.PA. contributed equally to this work.
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In the current design, a single CTV unit provides a rigid hemicryptophane framework
for the synthesis of a novel gyroscope-inspired molecule. Our design incorporates a novel
combination of features: (i) efficient, high-yielding synthetic scheme, (ii) multiple, proximate
rotators in one covalently bonded molecular system, (iii) exclusion of other molecules and ions
from the stator interior that may impede rotator motion, and (iv) hindered rotators experiencing
friction through exposure to solvent.

Figure 6.1. Gyroscope-Inspired Tribenzylamine Hemicryptophane (5) Possessing a Rigid Stator (a
and c) and Three Rotator Groups (b). Arrows illustrate rotation but are not intended to suggest
unidirectionality.

Gyroscope-inspired molecular systems have focused largely on approaching
barrierless rotation of isolated or sequestered rotors. One of the first examples (also referred
to as a molecular turnstile) was synthesized by Moore and Bedard [33,34]. The creative
design included a rigid hexakis(phenylacetylene) framework that preserved the low barrier of
rotation about the 1,4-axis of the substituted p-phenylene moiety. Garcia-Garibay and coworkers extended these ideas in the construction of amphidynamic crystals [11,15,35-54],
where the introduction of bulky substituents creates sufficient space in the lattice framework to
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allow near barrierless rotation of the central p-phenylene group. Furthermore, the p-phenylene
moiety can be functionalized to create a dipole moment that could be used for controlling
motion with an external electric field [11,36-38,42]. Following a different approach, Gladysz
and co-workers prepared a series of metal-centered molecular gyroscopes in which the rotator
is protected by three-spoke structures as part of the stator. The rotational dynamics of these
gyroscopes were studied in solution and their crystal structures indicated sufficient free
volume around the rotator to allow low-barrier rotation [9,55-59]. Most recently, Kitagawa et al.
designed a self-assembled supramolecular gyroscope where the stator is a heterocapsule
formed by noncovalent interactions and the rotator is an encapsulated guest [60].
Herein, we report a streamlined synthesis of a gyroscope-inspired tribenzylamine
hemicryptophane (5, Figure 6.2) involving multiple hindered rotators, where fast rotation is
1

observed by H NMR spectroscopy above a critical temperature. Rotations about the 1,4-axis
of the three p-phenylene rotators encased in a rigid CTV-trismethylamine stator were
1

investigated using H variable temperature (VT) NMR spectroscopy and molecular dynamics
(MD) simulations.

Figure 6.2. Three-Step Synthesis of Gyroscope-Inspired Tribenzylamine Hemicryptophane 5.
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6.2 Results and Discussion
6.2.1 Synthesis and X-ray Crystal Structure of Hemicryptophane
In order to synthesize the gyroscope-inspired tribenzylamine hemicrytophane 5, the
linkers (including the rotators) were first cyclized in the rigid CTV framework and then closed
with an amine to form the final three-dimensional structure (Figure 6.2). Reaction of
commercially available vanillyl alcohol 1 and dibromo-p-xylene 2 gave the versatile linker 3 in
65% yield. Cyclization of 3 was achieved with a catalytic amount of Sc(OTf)3 in acetonitrile to
afford the “gyroscope scaffold intermediate” 4 in 29% yield. This reaction was based on
previous protocols where various 3,4-disubstituted benzyl alcohols were treated with catalytic
Sc(OTf)3 to prepare CTV and cryptophane derivatives [18]. Compound 4 was reacted with 7 N
NH3 in MeOH to give 5 in 67% yield, with an overall yield of 13% for the three steps.
1

Compound 5 was characterized by solution H NMR and

13

C NMR spectroscopy, high-

resolution mass spectrometry (using the electrospray ionization method), and X-ray
crystallography. This short synthetic scheme utilizes mild conditions and results in high overall
yields. Moreover, this route provides ample versatility by increasing the number of methylene
spacer units or introducing new functional groups on 3 to form rotators with different
conformations, rotation barriers, and dipole moments.
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a)

b)

c)
N1-C32
N1-C48
N1-C16
C32-C29
C48-C45
C16-C13
C32-N1-C48
C48-N1-C16
C32-N1-C16
N1-C32 -C29
N1-C48 -C45
N1-C16 -C13
O2-C9 -C10 -C15
O6-C41 -C42 -C43
O4-C25 -C26 -C31

1.466 (2) Å
1.464 (2) Å
1.461 (2) Å
1.509 (2) Å
1.512 (3) Å
1.514 (3) Å
114.84 (14 )°
113.96 (14 )°
114.45 (14 )°
108.93 (14 )°
109.15 (14 )°
110.18 (14 )°
86.1 (2 )°
85.4 (2 )°
93.8 (2 )°

C28-C29-C32-N1
O2-C9 -C10 -C11
O6-C41 -C42 -C47
O4-C25 -C26 -C27
C14-C13-C16-N1
C13-C16-N1-C48
C30-C29-C32-N1
C29-C32-N1-C16
C44-C45-C48-N1
C45-C48-N1-C32
C12-C13-C16-N1
C46-C45-C48-N1
C13-C16-N1-C32
C29-C32-N1-C48
C45-C48-N1-C16

97.7 (2 )°
-90.9 (2 )°
-89.1 (2 )°
-83.1 (2 )°
-61.5 (2 )°
-84.9 (2 )°
-77.7 (2 )°
-75.4 (2 )°
-66.6 (2 )°
-79.4 (2 )°
117.2 (2)°
107.6 (2)°
140.2 (2 )°
150.05 (13 )°
145.83 (14 )°

Figure 6.3. (a) ORTEP Representations for 5 With Atom Labels. (b) Space-Filling Side and Bottom
View of 5. Atom Color Code: C is Gray, O is Red, N is Blue, and H is White. (c) Selected Bond
Lengths (Å), Angles (° ) and Dihedral Angles (°) of Compound 5.

The X-ray crystal structure of 5 indicates the three rotators adopt a propeller
conformation (Figure 6.3). 5 crystallizes in the monoclinic space group P21/c and each unit cell
consists of four molecules with two of each enantiomer (Figure 6.3). In both enantiomers the
p-phenylene rotators are oriented edgewise into the interior (angled away from the methoxy
group ortho to them) with an average dihedral angle of ~ 88.1° for O-Cbenzyl-Cphenyl-Cphenyl, ~ 68.6° for N-Cbenzyl-Cphenyl-Cinterior-phenyl and ~ 107.5° for N-Cbenzyl-Cphenyl-Cexterior-phenyl (see Figure
6.3c). The minimal distance from the phenylic proton on C44 (pointing into the cage) to the
plane described by the next aryl ring (C10 to C15) is relatively small at 3.22 Å. After the van
der Waals radii for hydrogen and carbon are included [61], the “clearance” distance is
approximately 0.32 Å. The distance from the same proton to the nitrogen atom was even
shorter at 2.97 Å, with clearance distance of 0.22 Å when van der Waals radii are included, as
the nitrogen is oriented into the interior with an average C–N–C bond angle of 114.42° (see
Figure 6.3c). This propeller-shaped conformation with a pyramidal nitrogen atom where the
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lone pair is pointed into the cage is similar to the crystal structure of tribenzylamine, where the
rigid CTV is not present [62]. It is believed that this conformation is primarily favored due to
steric hindrance [62]. Despite the propeller conformation of the rotators and the positioning of
the nitrogen atom into the interior of the cage, rotator motion is expected given the observed
clearance distances (Figure 6.3).
Unlike some previously reported porous gyroscopes [58], which encountered barriers
to rotation due to the intercalation of solvent molecules (or neighboring molecules in solid
state), the small internal volume in 5 should prevent guest encapsulation. Indeed, X-ray
crystallography indicated an empty tribenzylamine hemicryptophane, lacking solvent
molecules. Small molecules such as helium, dihydrogen, dinitrogen and xenon were not
observed to bind to 5 at 1 atm over a range of temperatures, +47 °C to -93 °C. Molecular
dynamics simulations were also in agreement with the experimental findings and suggest that
these small molecular species should be excluded from the interior. Computational modeling
was used to explore effects due to rotation of the p-phenylene rotators. GRASP [63] was
employed in order to investigate whether a potential interior cavity within 5 emerges with
rotation of the rotators. With a probe radius of 1.4 Å, only in improbable, high-energy
-1

structures ( E > 30 kcal mol , where

E is the energy relative to the X-ray structure) where

the angle of each p-phenylene rotator increased by 90° relative to the crystal structure was a
cavity identified. This suggests that a cavity of sufficient volume to accommodate small guest
molecules is essentially nonexistent, thereby preventing the inclusion of small molecules that
may hinder p-phenylene rotation.

1

6.2.2 H VT-NMR Experiments with Hemicryptophane 5
In order to investigate the energy barrier of the rotators in solution phase, we
1

performed a H VT-NMR study of 5 in CD2Cl2 from -93 °C to +27 °C. The NMR spectra in
Figure 6.4 indicate that the rotational rate of the p-phenylene rotators became slow on the
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NMR timescale as the temperature was decreased. At 27 °C, the four protons (labeled H2, H3,
H4 and H5 in Figure 6.4a) on each of the three rotators were split into two doublets at 6.1 ppm
(average signal from H2 and H4) and 6.9 ppm (average signal from H3 and H5). Upon cooling,
these doublets became broader and the energy barrier for p-phenylene rotation was estimated
-1

using equations 6-1 and 6-2 [64], to be 9.2 kcal mol from the coalescence temperature (ca. 2300 Hz). As the temperature was further reduced to -93 °C, a new pair of

70 °C; kcoalesce

doublets of equal intensity (three protons each) arose for each doublet that coalesced. This
led to splitting of the doublet for H2 and H5 and also H 3 and H4, where H2 and H3 shift upfield
as they are pointed into the cavity while H4 and H5 are oriented away from the cavity. The H3H5 splitting pattern (Figure 6.4b) evidences that p-phenylene rotation at -93 °C is slow on the
NMR time scale, trot > 3 ms. Similar temperature-dependent behavior was recently reported for
a 2,3-dichlorophenylene rotator caged within a polysilaalkane stator [65]. In line with our
1

design, the stator remained rigid throughout the H VT-NMR dataset as indicated by the fact
that the integration and splitting pattern of all CTV-trismethylamine proton peaks were
constant. It is also interesting to note that protons HA1 and HA2 remained diastereotopic
1

1

1

throughout the H VT-NMR series (Figure 6.4b). All peaks were assigned by H- H NOESY
experiment (Figure 6.5).
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1

Figure 6.4. (a) Schematic Model of the Molecular Motion of 5. (b) H VT-NMR Spectra of 5
Measured in CD2Cl2 With 500 MHz Spectrometer.

Figure 6.5.

1

1

H- H NOESY Spectrum of 5 in CDCl3 at 27 °C With 500 MHz Spectrometer to

Determine the Assignment of Protons.
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6.2.3 Molecular Dynamics Simulations
To investigate the conformational fluctuations of the rotators and stator, MD
simulations were carried out on 5 (Figure 6.6). One of the crystal structures was used as the
initial structure, and the length of the simulations was 50 ns. Equilibration was confirmed by
monitoring relaxation of structural parameters.
conformations of the rotators were selected: (

Three dihedral angles that reflect the

N1-C16-C13-C14,

N1-C32-C29-C30 and

N1-C48-C45-C44). The symmetry of the structure yields nearly identical average values of
these angles that are in agreement with the values observed in the crystal structure:
72.3° ± 10°,

= -71.8° ± 10° and

= -

= -72.8° ± 10°; the uncertainties (fluctuations) are one

standard deviation. The MD simulations at 25 °C indicated limited fluctuations within the
structure on the nanosecond time scale (Figure 6.6), and the CTV unit that forms the stator
remains highly rigid, in agreement with the NMR results noted above. The p-phenylene units
are not observed to rotate and instead librate in a manner consistent with a hindered rotor that
rotates on a time scale > 100 ns. Therefore, simulations, X-ray, and NMR structural data all
agree that the propeller-shaped conformation is highly favored in 5. High temperatures were
artificially employed to observe rotation in the simulations: at 527 °C, rotations of the three pphenylenes are frequent, conformations where the rotators are directed edgewise into the
interior (similar to what is seen in the crystal structure) are preferentially populated, and no
preferred rotational direction in the three p-phenylenes is observed.
To investigate further the p-phenylene rotation and interactions among the rotators,
the crystal structure of 5 was minimized, and the dihedral angle

was systematically varied

(Figure 6.7). The structure was then relaxed via energy minimization, constraining the
coordinates of all atoms but those in the two remaining
is essentially invariant during the rotation. The
accommodate the 180° rotation of the

and

p-phenylene rings. The -ring

-ring only rotates at most 19.7° to

-ring. An energy barrier arises due to the steric

interaction between the -ring and -ring. Interestingly, the rotational energy barrier estimated
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-1

from this simplistic and highly constrained calculation (~12 kcal mol ) is consistent with the
1

-1

experimental value inferred from the H VT-NMR experiments (~10 kcal mol ). The modeling
results suggests that, though not entirely independent, the rotations of the

- and -rings are

only weakly coupled.

Figure 6.6. Orthogonal Views of 30 Superimposed Structures from the MD Simulation of 5. The
dihedral angles are indicated:

(magenta),

(cyan) and (yellow).
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Figure 6.7. Minimized Energy as a Function of

, Which is Rotation of the

Dihedral Angle

Relative to the Energy Minimized X-ray Structure (Gray). The crystal structure of 5 was minimized,
and the angle

was varied in 10° increments, driving rotation of the -ring (magenta). For each value of

, the structure was energy minimized, constraining the coordinates of all atoms but those in the two
remaining p-phenylene rotators:

-ring (cyan) and -ring (yellow). For clarity: the CTV moiety and

hydrogens are not shown; two carbons of the -ring are rendered black.

6.3 Conclusions
In summary, a novel gyroscope-inspired tribenzylamine hemicryptophane 5 was
synthesized in three steps in good overall yield using mild conditions. This synthetic route
offers the possibility of preparing hemicryptophanes with multiple, proximate rotators, where
the molecular properties of the rotators can be varied by changing the length and composition
of the linkers used to cyclize the “gyroscope scaffold intermediate” 4. The compact size of the
cavity in this system helps to avoid the inclusion of solvent and gaseous molecules that have
1

the potential to inhibit rotation. H VT-NMR data indicate a critical temperature for the onset of
rotation on the sub-millisecond time scale and a hindered, dynamic motion of these three
rotators at room temperature. The desired rigidity of the CTV stator and the rotator properties
1

of the p-phenylenes were corroborated by H VT-NMR spectroscopy and MD simulations. As
a p-phenylene ring rotates, it encounters one of the neighboring p-phenylenes, leading to a
steric barrier that hinders rotation. Rotation of the rings appears not to be strongly correlated
with one another.
The compact size and molecular motions of 5 make it a compelling initial motif from
which to engineer unidirectional, potentially coupled rotators for molecular locomotion or
transmitting torque. Towards this goal, it may be possible to introduce sterically bulky
substituents on the linkers to control the temperatures at which rotation becomes accessible
and to favor one direction of rotation. Different substituent groups can also be introduced to
create a dipole moment on the rotators, thereby allowing the use of electric fields to explore
rapid conformational response in these systems and to control the direction of rotation.
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6.4 Experimental Procedures
1

6.4.1 Calculating from H VT-NMR Data the Energy Barrier for p-Phenylene Rotation
Equation 6-1 was used to determine the p-phenylene rotation rate at the coalescence
temperature:

k=

v0
2

(6-1)

where k is the rate coefficient, v0 = vA-vB is the chemical shift difference (in Hz) between the
two separate signals at slow exchange (in this case at -93 °C or 180 K). The Arrhenius
equation (6-2) was used to determine the activation energy, Ea, at the coalescence
temperature, T (in K):

ln(k / Hz ) =

Ea 1
+ ln(A / Hz )
R T

(6-2)

where A is the pre-exponential factor and R is the universal gas constant [64].

6.4.2 Computational Methods
All-atom MD simulations were carried out using NAMD2 [66]. The internal bonded
parameters were obtained from AMBER-94 [67], and the nonbonded parameters were
proposed in previous studies [68-72]. Simulations were performed in the absence of solvent at
25 °C and temperature was controlled using Langevin dynamics with a damping coefficient of
-1

5 ps . The time step of the simulations was 0.5 fs. Relaxation calculations using energy
minimization consist of up to 10,000 steps of the conjugate gradient algorithm as implemented
in NAMD2; energy was monitored to confirm minimization [66].
GRASP [63] was employed to investigate a potential interior cavity within 5. Different
conformations were generated by manual rotations of the three p-phenylenes. The rotations
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were systematically performed in 10° increments using one of the crystal structures of 5 as
reference. A probe radius of 1.4 Å was used for all calculations.

For details about more “Experimental Procedures”: Reagents, and Crystal growth and
†

†

X-ray crystallography, the reader is referred to Najat S. Khan , Jose Manuel Perez-Aguilar ,
Tara Kaufmann, P. Aru Hill, Olena Taratula, One-Sun Lee, Patrick J. Carroll, Jeffery G. Saven,
Ivan J. Dmochowski. “Multiple Hindered Rotators in a Gyroscope-Inspired Tribenzylamine
†

Hemicryptophane”, Journal Of Organic Chemistry, 2011, 76: 1418-1424. ( Equal contribution)
Also the available supporting information.
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7

Final Remarks

7.1 Conclusions
In this dissertation, protein systems of varying degrees of complexity were studied
using a variety of computational approaches. Also, similar computational methodologies were
utilized to study different molecular systems. The computational design approach based on a
statistical entropy-based formalism (described in detail in Chapter 2) was used to designed
and redesigned different protein systems [1-3]. This approach represented the core
methodology of most all the projects described (Chapter 3). All-atom molecular dynamics
simulations were used to complement the computational design methods and to extend our
understanding of the protein systems under investigation, e.g., SDF-1 (Chapter 5). Two other
techniques were used to better understand some of the studied systems: docking calculations
and comparative modeling. Docking calculations were used to identify the location and the
different poses of ligand molecules into receptors, particularly G protein-coupled receptors
(GPCRs) (Chapter 4). Comparative or homology modeling techniques were extensively used
to model the structures of GPCRs, e.g., the human
The study of the human

opiod receptor (Chapter 4).

opioid receptor, a G protein-coupled receptor, exemplifies

the necessity of using many different computational techniques. In generating water-soluble
variants for this important receptor, comparative modeling techniques were required to obtain
reliable models necessary for computational protein design. As discussed in Chapter 4, the
generation of reliable models of the wild type protein by itself is a complex and subtle problem.
Something that was particularly useful to guide our modeling was the information collected
from mutagenesis studies. Also extremely important for the modeling was the sequence
alignment, which is often the essential determining step in comparative modeling protocols. A
final consensus was used based on different pairwise sequence alignments programs (see
Chapter 4), and the alignment obtained using BLASTp [4] with the Blosum62 [5] substitution
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matrix was in close agreement with the consensus alignment. In subsequent modeling
projects, the combination BLASTp/Blosum62 is likely to yield suitable alignments. We also
found that considering the information from the highly conserved fingerprint residues for the
rhodopsin-like GPCR family facilitates the generation of reliable structures. Additionally, the
use of docking methodologies could provide another way to corroborate specific protein/ligand
interactions and, as a consequence, assist in the determination of reliable models. After
generating reliable models, the statistical entropy-based formalism will be used to redesign the
membrane protein so as to generate water-soluble variants. To test the robustness of the
designed structures, all-atom MD simulations will be carried out in aqueous environment
under physiological conditions of pressure and temperature.
During our work we identified tools that were valuable in providing insight and
analyzing computational and experimental findings. Particular in the case of the designed
water-soluble transmembrane

1 domain from the nicotinic acetylcholine receptor (WSA),

secondary structure prediction servers were used to predict the locations and lengths of the
helices in the water-soluble analog. Different prediction servers were used (PSIPRED [6],
SABLE [7], PORTER [8]), but we found that the protein secondary structure prediction server
PORTER (http://distill.ucd.ie/porter/), predicted results that were in closest agreement with the
NMR-derived structures of WSA. In addition, during the creation of models for a GPCR (
opioid receptor), the second extracellular loop (EC2) was problematic in the sense that the
sequence identity with the current available structures is generaly low [9]. Using the same
servers mentioned above, we predicted the secondary structure of EC2 for the currently
available GPCR structures. The results from PORTER for assigning secondary structure were
more in agreement with the secondary structures observed in
1

2

(PDB accession 2RH1) and

(PDB accession 2VT4) adrenergic receptor, bovine rhodopsin (PDB accession 1U19), A2A

adenosine receptor (PDB accession 3EML) and the D3 dopamine receptor (PDB accession
3PBL).
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Loop modeling was a technique that was utilized to generate and assay different
length loops that connect the N- and C-termini in our work with the SDF-1 analogs (Chapter
5). Although this approach provides no explicit information about structural stability or
dynamics, we found it useful to guide the design of these loops and some of the general
conclusions from these systems. The loop building and refinement was done using the
program Modeller [10,11]. This approach to candidate loop construction offers an easy and
low computational cost technique.
Lastly, for the calculation of cavities in proteins, both CASTp [12] and GRASP [13]
were found to be useful. While studying smaller molecular systems such as the case of our
work with the gyroscope-inspired tribenzylamine hemicryptophane (Chapter 6), GRASP was
the preferred choice in calculating cavity volumes. The reason was that GRASP was capable
to calculate the volume of the small central cavity of this system. Programs such as CASTp
are designed to work with relatively larger cavities such as those found in proteins.

7.2 Ongoing and Future Directions
We close with a few comments regarding ongoing work and potential new research
directions.
Regarding the work done in the case of WSA (chapter 3), it will be interesting to
explore the transmembrane structures of this important receptor, including those of the other
subunits and oligomers of transmembrane domains.
As previoulsly mentioned, although significant effort was put into modeling the
structure of the human

opioid receptor, the final goal was to use the model to design of

water-soluble analogs of this important GPCR. Early experimental results are promising in this
regard, and it will be of interest to further explore the extent to which the designed protein is
consistent with the expected structurally and functionally related properties. In addition, it will
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be of interest to vary the numbers of residues mutated and use more than one model in
generating designed, water-soluble sequences.
In the case of SDF-1 , the information provided from cell-based assays, i.e., Boyden
chamber and CXCR4 activation assays, will be compared with the analysis of the molecular
dynamics simulations in an effort to provide a molecular interpretation of the activities of
designed sequences. These simplified analogs open new possibilities to generate analogs
were the MD simulations could be performed to predict the dynamics and binding properties
as well as the extent to which such findings can be extrapolated to understand and specify the
chemotactic and perhaps even the angiogenic properties of the peptides. Possible routes to
improving the peptides are the removal of site(s) known to be the targets of proteases as well
as redesign of the current cysteine residues that in SDF-1 form conserved disulfide bonds.
In the case of the hemicryptophane molecules (Chapter 6), the molecular simulations
and modeling were in excellent agreement with the observed conformational dynamics and
structures of these molecules. Similar computational methodologies could be used to explore
and design other molecules containing internal rotors (gyroscopes) and flexible internal
degrees of freedom.

7.3 References
1. Saven JG, Wolynes PG: Statistical mechanics of the combinatorial synthesis and
analysis of folding macromolecules. Journal of Physical Chemistry B 1997, 101:83758389.
2. Zou JM, Saven JG: Statistical theory of combinatorial libraries of folding proteins:
Energetic discrimination of a target structure. Journal of Molecular Biology 2000,
296:281-294.

154

3. Kono H, Saven JG: Statistical theory for protein combinatorial libraries. Packing
interactions, backbone flexibility, and the sequence variability of a main-chain
structure. Journal of Molecular Biology 2001, 306:607-628.
4. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment search tool.
J Mol Biol 1990, 215:403-410.
5. Henikoff S, Henikoff JG: Amino acid substitution matrices from protein blocks. Proc
Natl Acad Sci U S A 1992, 89:10915-10919.
6. Buchan DW, Ward SM, Lobley AE, Nugent TC, Bryson K, Jones DT: Protein annotation
and modelling servers at University College London. Nucleic Acids Res 38:W563-568.
7. Adamczak R, Porollo A, Meller J: Combining prediction of secondary structure and
solvent accessibility in proteins. Proteins 2005, 59:467-475.
8. Pollastri G, McLysaght A: Porter: a new, accurate server for protein secondary
structure prediction. Bioinformatics 2005, 21:1719-1720.
9. Worth CL, Kleinau G, Krause G: Comparative sequence and structural analyses of Gprotein-coupled receptor crystal structures and implications for molecular models.
PLoS One 2009, 4:e7011.
10. Sali A, Blundell TL: Comparative protein modeling by satisfaction of spatial
restraints. Journal of Molecular Biology 1993, 234:779-815.
11. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen MY, Pieper U,
Sali A: Comparative protein structure modeling using Modeller. Curr Protoc
Bioinformatics 2006, Chapter 5:Unit 5 6.
12. Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J: CASTp: computed atlas
of surface topography of proteins with structural and topographical mapping of
functionally annotated residues. Nucleic Acids Res 2006, 34:W116-118.

155

13. Nicholls A, Sharp KA, Honig B: Protein folding and association: insights from the
interfacial and thermodynamic properties of hydrocarbons. Proteins 1991, 11:281296.

156

